Document:

Exhibit 10.15

 

CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION
(I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED.

  

IMMUNOME, INC.

AND

MASSACHUSETTS INSTITUTE OF TECHNOLOGY

as licensing agent for

WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH

EXCLUSIVE PATENT LICENSE AGREEMENT

     

     

    

  

TABLE OF CONTENTS

 

 

	R E C I T A L S	1

 

		1.	DEFINITIONS.	1

 

		2.	GRANT OF RIGHTS.	4

 

		3.	COMPANY DILIGENCE OBLIGATIONS.	5

 

		4.	ROYALTIES AND PAYMENT TERMS.	6

 

		5.	REPORTS AND RECORDS.	11

 

		6.	PATENT PROSECUTION.	12

 

		7.	INFRINGEMENT.	13

 

		8.	INDEMNIFICATION AND INSURANCE	14

 

		9.	NO REPRESENTATIONS OR WARRANTIES	15

 

		10.	ASSIGNMENT.	16

 

		11.	GENERAL COMPLIANCE WITH LAWS	16

 

		12.	TERMINATION	17

 

		13.	DISPUTE RESOLUTION.	18

 

		14.	MISCELLANEOUS.	19

 

	APPENDIX A 	22

 

	APPENDIX B 	23

  

    -i-

     

    

 

WHITEHEAD
INSTITUTE FOR BIOMEDICAL RESEARCH

MASSACHUSETTS INSTITUTE OF TECHNOLOGY

EXCLUSIVE PATENT LICENSE AGREEMENT

 

This Agreement, effective
as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is among the Massachusetts
Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue,
Cambridge, MA 02139-4307, the Whitehead Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, with
a principal office at Nine Cambridge Center, Cambridge, Massachusetts 02142, and Immunome, Inc. (“COMPANY”), a Pennsylvania
corporation, with a principal place of business at 100 Lancaster Avenue, Wynnewood, PA 19096.

 

R E C I T A L S

 

WHEREAS, WHITEHEAD
is the owner of certain PATENT RIGHTS (as later defined herein) and TANGIBLE PROPERTY relating to Whitehead Case No. [***], and
has the right to grant licenses under said PATENT RIGHTS;

 

WHEREAS, WHITEHEAD
has authorized M.I.T. to act as its sole and exclusive agent for the purposes of licensing the PATENT RIGHTS and TANGIBLE PROPERTY,
and has authorized M.I.T. to enter into this Agreement on its behalf;

 

WHEREAS, M.I.T. and
WHITEHEAD desire to have the PATENT RIGHTS and TANGIBLE PROPERTY commercialized to benefit the public and M.I.T. is willing to
grant a license thereunder;

 

WHEREAS, COMPANY has
represented to M.I.T., to induce M.I.T. to enter into this Agreement, that COMPANY shall commit itself to a thorough, vigorous
and diligent program of exploiting the PATENT RIGHTS and TANGIBLE PROPERTY so that public utilization shall result therefrom; and

 

WHEREAS, [***], an
inventor of the PATENT RIGHTS, has or will shortly [***];

 

WHEREAS, COMPANY desires
to obtain a license under the PATENT RIGHTS and TANGIBLE PROPERTY upon the terms and conditions hereinafter set forth.

 

NOW, THEREFORE, M.I.T.,
WHITEHEAD and COMPANY hereby agree as follows:

 

1.                  
DEFINITIONS.

 

1.1               
“AFFILIATE” shall mean any legal entity (such as a corporation, partnership, or limited liability company)
that is controlled by COMPANY. For the purposes of this definition, the term “control” means (i) beneficial ownership
of at least fifty percent (50%) of the voting securities of a corporation or other business organization with voting securities
or (ii) a fifty percent (50%) or greater interest in the net assets or profits of a partnership or other business organization
without voting securities.

 

     

     

    

 

1.2               
 “CORPORATE PARTNER” shall mean any entity which agrees to compensate COMPANY or an AFFILIATE or SUBLICENSEE
for COMPANY’s, AFFILIATE’s or SUBLICENSEE’s practice of the PATENT RIGHTS, LICENSED PRODUCTS, , DISCOVERED PRODUCTS,
and/or LICENSED PROCESSES on behalf of or in collaboration with such entity, including without limitation for discovery and development
activities for LICENSED PRODUCTS, DISCOVERED PRODUCTS, and/or LICENSED PROCESSES.

 

Any entity which meets
the foregoing criteria, that also receives a sublicense of the PATENT RIGHTS shall be considered a SUBLICENSEE, and not a CORPORATE
PARTNER, for the purposes of this Agreement.

 

1.3               
“CORPORATE PARTNER INCOME” shall mean [***].

 

1.4               
“CORPORATE PARTNER RESEARCH SUPPORT PAYMENTS” shall mean [***].

 

1.5               
“DISCOVERED PRODUCT” shall mean any product or derivative thereof that was identified, selected or determined
to have utility in whole or in part by the use or modification of a LICENSED PRODUCT or the use of LICENSED PROCESSES. DISCOVERED
PRODUCTS shall include, [***]. DISCOVERED PRODUCTS shall not include targets or modulation of targets using anything other than
a [***]. For any DISCOVERED PRODUCT that also falls within the definition of LICENSED PRODUCT, such DISCOVERED PRODUCT shall be
deemed a LICENSED PRODUCT for the purposes of this Agreement.

 

1.6               
“FIELD” shall mean collectively FIELD 1 and FIELD 2 and FIELD 3.

 

1.7               
“FIELD 1” shall mean therapeutics and diagnostics.

 

1.8               
“FIELD 2” shall mean solely for research reagent purposes: Not for use in humans, not for therapeutic
purposes, and not for diagnostic purposes.

 

1.9               
“FIELD 3” shall mean all but for FIELD 1 and FIELD 2.

 

1.10            
“LICENSED PROCESS” shall mean any process that, in whole or in part:

 

(i)                 
absent the license granted hereunder, would infringe one or more claims of the PATENT RIGHTS; or

 

(ii)               
when practiced, uses a LICENSED PRODUCT, as defined in Section 1.11(i).

 

1.11            
“LICENSED PRODUCT” shall mean shall mean any product that, in whole or in part:

 

(i)                 
absent the license granted hereunder, would infringe one or more claims of the PATENT RIGHTS; or

 

(ii)               
is manufactured by using a LICENSED PROCESS or that, when used, practices a LICENSED PROCESS, as defined in Section 1.10(i).

 

1.12            
“LICENSED SERVICE” shall mean any service COMPANY or an AFFILIATE or SUBLICENSEE performs for a third
party that cannot be developed or performed, whole or in part, without COMPANY using a LICENSED PRODUCT or DISCOVERED PRODUCT,
or performing a LICENSED PROCESS.

 

1.13            
“NET SALES” shall mean [***] less the following:

 

(i)               
[***];

 

(ii)              
[***];

 

(iii)             
[***]; and

 

    -2-

     

    

 

(iv)              
 [***].

[***]

 

1.14            
“PATENT CHALLENGE” shall mean a challenge to the validity, patentability, enforceability and/or non-infringement
of any of the PATENT RIGHTS (as defined below) or otherwise opposing any of the PATENT RIGHTS.

 

1.15            
“PATENT RIGHTS” shall mean:

 

(a)                
the United States patent listed on Appendix A;

 

(b)               
the United States patent application and/or provisional applications listed on Appendix A and the resulting patents;

 

(c)                
any patent applications resulting from the provisional applications listed on Appendix A, and any divisionals, continuations,
continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the
patent applications listed on Appendix A and of such patent applications that result from the provisional applications listed
on Appendix A, to the extent the claims are directed to subject matter specifically described in the patent applications
listed on Appendix A, and the resulting patents;

 

(d)               
any patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents) of the
patents described in (a), (b), and (c) above.

 

1.16            
“POLYPEPTIDE” shall mean a protein or polypeptide manufactured using a LICENSED PROCESS or a LICENSED
PRODUCT. For avoidance of doubt and the purposes of this agreement, POLYPEPTIDE is a LICENSED PRODUCT.

 

1.17            
“REPORTING PERIOD” shall begin on the first day of each calendar quarter and end on the last day of such
calendar quarter.

 

1.18            
“SERVICE INCOME” shall mean [***].

 

1.19            
“SUBLICENSE INCOME” shall mean [***].

 

1.20            
“SUBLICENSEE” shall mean any non-AFFILIATE sublicensee of the rights granted COMPANY under Section 2.1.

 

1.21            
“SUBLICENSEE RESEARCH SUPPORT PAYMENTS” shall mean [***].

 

1.22            
“TANGIBLE PROPERTY” shall mean the specific biological and/or chemical material, whether by itself or
incorporated into another material, described in Appendix B; and any progeny and unmodified derivatives.

 

1.23            
“TERM” shall mean the term of this Agreement, which shall commence on the EFFECTIVE DATE and shall remain
in effect until the expiration or abandonment of all issued patents and filed patent applications within the PATENT RIGHTS, unless
earlier terminated in accordance with the provisions of this Agreement.

 

1.24            
“TERRITORY” shall mean United States of America.

 

    -3-

     

    

 

2.                  
GRANT OF RIGHTS.

 

2.1               
License Grants.

 

(a)                
 PATENT RIGHTS. Subject to the terms of this Agreement, M.I.T. and WHITEHEAD hereby grant to COMPANY and its AFFILIATES
for the TERM a royalty-bearing license under the PATENT RIGHTS to develop, make, have made, use, sell, offer to sell, lease, and
import LICENSED PRODUCTS (including, but not limited to, POLYPEPTIDES) in the FIELD in the TERRITORY and to develop and perform
LICENSED PROCESSES and perform LICENSED SERVICES in the FIELD in the TERRITORY.

 

(b)               
TANGIBLE PROPERTY. Subject to the terms of this Agreement, M.I.T. and WHITEHEAD hereby grants to COMPANY and its
AFFILIATES for the TERM a royalty-bearing non-exclusive license to use the TANGIBLE PROPERTY to develop, make, have made, use,
sell, offer to sell, lease, and import LICENSED PRODUCTS (including, but not limited to, POLYPEPTIDES) in the FIELD in the TERRITORY
and to develop and perform LICENSED PROCESSES and perform LICENSED SERVICES in the FIELD in the TERRITORY. Legal title to the TANGIBLE
PROPERTY will remain with WHITEHEAD.

 

2.2               
Exclusivity. M.I.T. and WHITEHEAD agree that they shall not grant any other license under the PATENT RIGHTS to make,
have made, use, sell, lease and import LICENSED PRODUCTS (including, but not limited to, POLYPEPTIDES) in the FIELD in the TERRITORY
or to perform LICENSED PROCESSES or LICENSED SERVICES in the FIELD in the TERRITORY during the TERM, unless the conditions set
forth in section 2.4(b) occur and are not remedied by the COMPANY (herein defined as “EXCLUSIVE PERIOD”).

 

2.3               
Sublicenses.

 

(a)                
PATENT RIGHTS. COMPANY shall have the right to grant sublicenses of its rights under Section 2.1(a). COMPANY shall
incorporate terms and conditions into its sublicense agreements sufficient to enable COMPANY to comply with this Agreement. COMPANY
shall also include provisions in all sublicenses to provide that in the event that SUBLICENSEE brings a PATENT CHALLENGE against
WHITEHEAD or assists another party in bringing a PATENT CHALLENGE against WHITEHEAD (except as required under a court order or
subpoena) then COMPANY may terminate the sublicense. COMPANY shall promptly furnish M.I.T. with a fully signed photocopy of any
sublicense agreement. Upon termination of this Agreement for any reason, any SUBLICENSEE not then in default shall have the right
to seek a license from WHITEHEAD. WHITEHEAD agrees to negotiate such licenses in good faith under reasonable terms and conditions.

 

(b)               
TANGIBLE PROPERTY. COMPANY shall have the right to grant sublicenses of its rights under Section 2.1(b) only in the
context of a bona fide written agreement with one or more third parties for the development of LICENSED PRODUCTS and/or LICENSED
PROCESSES, which also includes a sublicense to COMPANY’s rights under the PATENT RIGHTS.

 

2.4               
[***].

 

(a)                
[***].

 

(b)               
[***].

 

2.5               
U.S. Manufacturing. COMPANY agrees that any LICENSED PRODUCT and/or LICENSED PROCESS used or sold in the United States
will be manufactured substantially in the United States.

 

    -4-

     

    

 

2.6               
Retained Rights.

 

(a)                
 Research and Educational Use. M.I.T. and WHITEHEAD retain the right on behalf of itself and all other non-profit
research institutes to practice under the PATENT RIGHTS and TANGIBLE PROPERTY for research, teaching, and educational purposes.

 

(b)               
Federal Government. COMPANY acknowledges that the U.S. federal government retains a royalty-free, non-exclusive,
non-transferable license to practice any government-funded invention claimed in any PATENT RIGHTS as set forth in 35 U.S.C. §§
201-211, and the regulations promulgated thereunder, as amended, or any successor statutes or regulations.

 

(c)                
[***].

 

2.7               
Ownership of Modifications. WHITEHEAD retains ownership of any TANGIBLE PROPERTY included or incorporated within
modifications.

 

2.8               
Transfer to Third Parties. COMPANY agrees not to transfer the TANGIBLE PROPERTY to any other parties, except to permitted
SUBLICENSEES as provided herein.

 

2.9               
No Additional Rights. Nothing in this Agreement shall be construed to confer any rights upon COMPANY by implication,
estoppel, or otherwise as to any technology or patent rights of M.I.T. or WHITEHEAD or any other entity other than the PATENT RIGHTS
and the TANGIBLE PROPERTY, regardless of whether such technology or patent rights shall be dominant or subordinate to any PATENT
RIGHTS or TANGIBLE PROPERTY.

 

3.                  
COMPANY DILIGENCE OBLIGATIONS.

 

3.1               
Diligence Requirements. COMPANY shall use diligent efforts, or shall cause its AFFILIATES and SUBLICENSEES to use
diligent efforts, to develop LICENSED PRODUCTS or LICENSED PROCESSES and to introduce LICENSED PRODUCTS or LICENSED PROCESSES into
the commercial market; thereafter, COMPANY or its AFFILIATES or SUBLICENSEES shall make LICENSED PRODUCTS or LICENSED PROCESSES
reasonably available to the public. Specifically, COMPANY or AFFILIATE or SUBLICENSEE shall fulfill the following obligations:

 

(a)               
[***].

 

(b)               
[***].

 

(c)               
[***].

 

(d)               
[***].

 

(e)               
[***].

 

(f)                
[***].

 

(g)               
[***].

 

(h)               
[***].

 

(i)                
[***].

 

(j)                
[***].

 

(k)               
[***].

 

(l)                 
[***].

  

    -5-

     

    

 

In the event that M.I.T.
determines that COMPANY has failed to fulfill any of its obligations under Sections 3.1(a) — 3.1(d), then M.I.T. may treat
such failure as a material breach in accordance with Section 12.3(b).

 

In the event that M.I.T.
determines that COMPANY (including an AFFILIATE or SUBLICENSEE) has failed to fulfill any of its obligations under Sections 3.1(e)
 — 3.1(j), then M.I.T. may treat such failure as a material breach in accordance with Section 12.3(b).

 

In the event that M.I.T.
determines that COMPANY (including an AFFILIATE or SUBLICENSEE) has failed to fulfill any of its obligations under Sections 3.1(k)
and 3.1(1), then M.I.T. may treat such failure as a material breach in accordance with Section 12.3(b), the EXCLUSIVE PERIOD for
FIELD 2 shall immediately expire, and M.I.T. may grant non-exclusive licenses to the PATENT RIGHTS in FIELD 2. Furthermore, COMPANY
shall not have the right to grant sublicenses under Section 2.3 of this Agreement in FIELD 2.

 

4.                  
ROYALTIES AND PAYMENT TERMS.

 

4.1               
Consideration for Grant of Rights.

 

(a)                
License Issue Fee and Patent Cost Reimbursement. COMPANY shall pay to WHITEHEAD on the three (3) month anniversary
of the EFFECTIVE DATE a license issue fee of Ten Thousand dollars ($10,000), and, in accordance with Section 6.3, shall reimburse
WHITEHEAD for its actual expenses incurred as of the EFFECTIVE DATE in connection with obtaining the PATENT RIGHTS. These payments
are nonrefundable.

 

(b)                License
Maintenance Fees. COMPANY shall pay to WHITEHEAD the below: following license maintenance fees on the dates set forth
below:

 

	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	January 1st of every year	 
	Thereafter during the TERM	 

 

This annual license maintenance
fee is nonrefundable; however, the license maintenance fee may be credited to running royalties subsequently due on NET SALES and
SERVICE INCOME earned during the same calendar year, if any. License maintenance fees paid in excess of running royalties due in
such calendar year shall not be creditable to amounts due for future years.

 

(c)                
Milestone Payments: COMPANY shall pay to WHITEHEAD the amounts below upon achievement by COMPANY or its AFFILIATE
of certain milestone events as set forth in the table below.

 

(i)                 
Payments will be due in respect of the achievement of the milestone events in the table below for the first LICENSED PRODUCT
or LICENSED PROCESS or POLYPEPTIDE in the first indication to reach a given milestone below:

 

 

	[***]:	[***]

 

    -6-

     

    

 

	[***]:	[***]
	[***]:	[***]
	[***]:	[***]

 

(ii)               
Payments will be due in respect of the achievement of the milestone events in the table below for each DISCOVERED PRODUCT
to reach the milestone below (payable for the first three occurrences only):

 

	[***]: 	[***]
	[***]:	[***]

 

COMPANY shall make such non-refundable, non-creditable milestone
payments within [***] after achievement of each of the milestones. For the convenience of the parties, in recognition of the value
of the PATENT RIGHTS, LICENSED PRODUCTS, POLYPEPTIDES, and LICENSED PROCESSES in identifying DISCOVERED PRODUCTS, and in the time
it takes to bring DISCOVERED PRODUCTS to market, COMPANY agrees to pay Milestone Payments under this Section. If the first LICENSED
PRODUCT, POLYPEPTIDE, LICENSED PROCESS or DISCOVERED PRODUCT does not meet all milestones, any paid milestone will be considered
fulfillment of that milestone obligation, which shall not be paid again on the next product to reach that milestone. Only milestones
that have not been paid previously will be paid. The obligation to pay Milestone Payments on each DISCOVERED PRODUCT shall survive
termination of this agreement as specified in section 12.5(a).

 

(iii)             
The milestone events set forth in Section 4.1(c) above are intended to be successive. In the event that any Phase I clinical
trial is combined with a Phase II clinical trial (i.e., a Phase I/II clinical trial), the milestone payment for the enrollment
of the first patient in a Phase I clinical trial shall be due upon the enrollment of the first patient in the Phase I/II clinical
trial; and in the event that any Phase II clinical trial is combined with a Phase III clinical trial (i.e., a Phase II/III clinical
trial), the milestone payment for the enrollment of the first patient in a Phase III clinical trial shall be due upon the enrollment
of the first patient in the Phase II/III clinical trial. In addition and notwithstanding the foregoing, if any milestone is reached
without achieving a preceding milestone, then the amount which would have been payable on achievement of the preceding milestone
shall be payable upon achievement of the following milestone.

 

(d)               
Running Royalties.

 

(i)                 
Running Royalties for FIELD 1.

 

(a)                
COMPANY shall pay to WHITEHEAD a running royalty of [***] of NET SALES in FIELD 1 of LICENSED PRODUCTS, and LICENSED PROCESSES
by COMPANY, AFFILIATES and SUBLICENSEES. Running royalties shall be payable for each REPORTING PERIOD and shall be due to WHITEHEAD
within [***] of the end of each REPORTING PERIOD.

  

(b)                COMPANY
shall pay to WHITEHEAD a running royalty of [***] NET SALES in FIELD 1 of DISCOVERED PRODUCTS by COMPANY, AFFILIATES and
SUBLICENSEES. Running royalties shall be payable for each REPORTING PERIOD and shall be due to WHITEHEAD within [***] of the
end of each REPORTING PERIOD.

 

    -7-

     

    

 

(ii)               
Running Royalties for FIELD 2. COMPANY shall pay to WHITEHEAD a running royalty of [***] of NET SALES in FIELD 2
of LICENSED PRODUCTS, DISCOVERED PRODUCTS, and LICENSED PROCESSES by COMPANY, AFFILIATES and SUBLICENSEES. Running royalties shall
be payable for each REPORTING PERIOD and shall be due to WHITEHEAD within [***] of the end of each REPORTING PERIOD.

 

(iii)             
Running Royalties for FIELD 3. At the time that COMPANY or AFFILIATES enter into a sublicense or written agreement
with a third party for the sale of LICENSED PRODUCTS or DISCOVERED PRODUCTS or LICENSED PROCESSES in FIELD 3 (or otherwise market
or sell LICENSED PRODUCTS or DISCOVERED PRODUCTS or LICENSED PROCESSES in FIELD 3), COMPANY shall notify M.I.T. and WHITEHEAD,
and the parties shall discuss in good faith a Running Royalty of NET SALES in FIELD 3. COMPANY and WHITEHEAD will enter into a
side letter to this Agreement with respect to Running Royalties of NET SALES in FIELD 3.

 

(iv)              
For the convenience of the parties, in recognition of the value of the PATENT RIGHTS, LICENSED PRODUCTS, POLYPEPTIDES, TANGIBLE
PROPERTY, and LICENSED PROCESSES in identifying DISCOVERED PRODUCTS, and in the time it takes to bring DISCOVERED PRODUCTS to market,
COMPANY agrees to pay royalties under this Section on each DISCOVERED PRODUCT for Seven (7) years after the first commercial sale
of each DISCOVERED PRODUCT. The obligation to pay running royalties on each DISCOVERED PRODUCT shall survive termination of this
agreement as specified in section 12.5(a).

 

(v)               
For clarification, COMPANY shall pay to WHITEHEAD running royalties on NET SALES of LICENSED PRODUCTS, and LICENSED PROCESSES,
the manufacture, use, sale, and/or import of which, absent the license granted hereunder, would infringe one or more claims of
the PATENT RIGHTS. For further clarification, COMPANY shall pay to WHITEHEAD running royalties on NET SALES of DISCOVERED PRODUCTS
manufactured, used, sold, and/or imported in the TERRITORY.

 

(e)                
Royalty Offset. If COMPANY or an AFFILIATE is obligated to pay royalties to one or more third parties in order to
obtain a license or similar right necessary to practice the PATENT RIGHTS, and COMPANY actually pays said third party royalties,
COMPANY shall be entitled to credit up to [***] of the amounts actually paid to such third parties against the royalties due to
WHITEHEAD under this Agreement in the same REPORTING PERIOD, provided, however, that in no event shall the royalty payments
under Section 4.1(d), when aggregated with any other offsets and credits allowed under this Agreement, be reduced by more than
[***] in any REPORTING PERIOD; provided, further, that COMPANY [***].

 

For clarification,
COMPANY may only offset royalties paid to third parties from the sales in the same country as the royalties due to WHITEHEAD. For
example, if COMPANY owes royalties to third parties for NET SALES in country Y and country Z, and COMPANY owes royalties to WHITEHEAD
for NET SALES in country Y, COMPANY may only offset third party royalties on NET SALES from country Y against royalties due to
WHITEHEAD for NET SALES in country Y.

  

    -8-

     

    

 

 For avoidance
of doubt, there is no royalty offset on DISCOVERED PRODUCTS.

 

(f)                 
Sharing of SERVICE INCOME. COMPANY shall pay to WHITEHEAD [***] of all SERVICE INCOME received by COMPANY and AFFILIATES
and SUBLICENSEES. Amounts shall be payable for each REPORTING PERIOD in which COMPANY receives SERVICE INCOME and shall be due
to WHITEHEAD within [***] of the end of each REPORTING PERIOD.

 

For clarification,
COMPANY shall pay to WHITEHEAD a percentage of SERVICE INCOME in any country where the performance of such LICENSED SERVICE (including
without limitation the manufacture, use, sale, and/or import of LICENSED PRODUCTS or LICENSED PROCESSES used in the provision of
such a service) would infringe one or more claims of the PATENT RIGHTS. For avoidance of doubt, there is no royalty offset under
this Sharing of SERVICE INCOME.

 

(g)                
SUBLICENSE INCOME.

 

(i)                 
Sharing of SUBLICENSE INCOME. In the event COMPANY or an AFFILIATE grants a sublicense of its rights under Section
2.1 of this Agreement, subject to Section 2.3, COMPANY shall pay WHITEHEAD a total of [***] of all SUBLICENSE INCOME received by
COMPANY or AFFILIATES from SUBLICENSEES.

 

(ii)                 
Bundling of PATENT RIGHTS. Notwithstanding the foregoing, if, in any sublicense of the PATENT RIGHTS, COMPANY or
an AFFILIATE also grants to the SUBLICENSEE rights to other patents owned or controlled by COMPANY or AFFILIATES that are necessary
to practice the PATENT RIGHTS, COMPANY will pay WHITEHEAD [***] of the total amount of SUBLICENSE INCOME received by COMPANY or
AFFILIATES from SUBLICENSEE under such agreement (hereinafter “BUNDLED SUBLICENSE”). For purposes of this subsection,
SUBLICENSE INCOME shall include the total amount of any payments received by COMPANY or an AFFILIATE from a SUBLICENSEE under any
such BUNDLED SUBLICENSE, whether or not specifically related to the PATENT RIGHTS. Such SUBLICENSE INCOME shall not be subject
to any adjustment to apportion value to a particular subset of patent rights within any such BUNDLED SUBLICENSE. COMPANY agrees
to share [***] of the total payments under the BUNDLED SUBLICENSE in exchange for: [***].

 

Any amounts due pursuant
Section 4.1(g) shall be payable for each REPORTING PERIOD and shall be due to WHITEHEAD within [***] of the end of each REPORTING
PERIOD.

 

(iii)                
Commercially Reasonable Consideration. Non-monetary consideration shall not be accepted by COMPANY or an AFFILIATE
for any sublicense of the PATENT RIGHTS without the prior written consent of WHITEHEAD, which shall not be unreasonably withheld
or delayed. Consideration for any and all sublicenses of the PATENT RIGHTS shall be on commercially reasonable terms and conditions
consistent with amounts paid for similar technology in the industry.

 

(h)                
CORPORATE PARTNER INCOME. COMPANY shall pay WHITEHEAD a total of [***] of all CORPORATE PARTNER INCOME received by
COMPANY and AFFILIATES and SUBLICENSEES. Such amount shall be payable for each REPORTING PERIOD and shall be due to WHITEHEAD within
[***] of the end of each REPORTING PERIOD.

 

    -9- 

     

    

 

(i)                   Consequences
of a PATENT CHALLENGE. In the event that (i) COMPANY or any of its AFFILIATES brings a PATENT CHALLENGE against WHITEHEAD,
or (ii) COMPANY or any of its AFFILIATES assists another party in bringing a PATENT CHALLENGE against WHITEHEAD (except as required
under a court order or subpoena), and (iii) WHITEHEAD does not choose to exercise its rights to terminate this Agreement pursuant
to Section 12.4, then [***]. In the event that such a PATENT CHALLENGE is successful, COMPANY [***]. In the event that a PATENT
CHALLENGE is unsuccessful, COMPANY [***].

 

(j)                 
No Multiple Royalties. If the manufacture, use, sublicense, or sale of any LICENSED PRODUCT or the performance of
any LICENSED PROCESS is covered by more than one of the PATENT RIGHTS, multiple royalties shall not be due.

 

(k)                 
Equity.

 

(i)                 
Initial Grant. COMPANY shall issue a total of ______________ (_____) shares of Common Stock of COMPANY, $1.011 par
value per share, (the “Shares”) in the name of WHITEHEAD and M.I.T. and of such persons as WHITEHEAD shall direct (“WHITEHEAD
Holder”), and each WHITEHEAD Holder shall receive such number of shares as WHITEHEAD shall direct. Such issuance shall be
recorded on the Stock Transfer Ledger of COMPANY on the EFFECTIVE DATE and the Shares shall be delivered to M.I.T., WHITEHEAD and
WHITEHEAD Holders, if any, within [***] of the EFFECTIVE DATE.

 

COMPANY represents to
WHITEHEAD and M.I.T. that, as of the Effective Date, the aggregate number of Shares equals [***] of the COMPANY’s issued
and outstanding Common Stock calculated on a “Fully Diluted Basis.” For purposes of this Section 4.1(k), “Fully
Diluted Basis” shall mean that the total number of issued and outstanding shares of the COMPANY’s Common Stock shall
be calculated to include conversion of all issued and outstanding securities then convertible into common stock, the exercise of
all then outstanding options and warrants to purchase shares of common stock, whether or not then exercisable, and shall assume
the issuance or grant of all securities reserved for issuance pursuant to any COMPANY stock or stock option plan in effect on the
date of the calculation.

 

(ii)                 
[***]

(iii)                
[***]

(iv)                
[***]

 

4.2         
Payments.

 

(a)                
Method of Payment. All payments under this Agreement should be made payable to “Whitehead Institute for Biomedical
Research” and sent to WHITEHEAD’s address identified in Section 14.1. Each payment should reference this Agreement
and identify the obligation under this Agreement that the payment satisfies.

 

(b)                 Payments
in U.S. Dollars. All payments due under this Agreement shall be drawn on a United States bank and shall be payable in
United States dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the
United States (as reported in the Wall Street Journal) on the last working day of the calendar quarter of the
applicable REPORTING PERIOD. Such payments shall be without deduction of exchange, collection, or other charges, and,
specifically, without deduction of withholding or similar taxes or other government imposed fees or taxes, except as
permitted in the definition of NET SALES.

 

    -10- 

     

    

 

(c)                 
Late Payments. Any payments by COMPANY that are not paid on or before the date such payments are due under this Agreement
shall bear interest, to the extent permitted by law, at two percentage points above the Prime Rate of interest as reported in the
Wall Street Journal on the date payment is due.

 

5.                  
REPORTS AND RECORDS.

 

5.1         
Frequency of Reports.

 

(a)                 
Before First Commercial Sale. Prior to the first commercial sale of any LICENSED PRODUCT, DISCOVERED PRODUCT, or
first commercial performance of any LICENSED PROCESS or LICENSED SERVICE, COMPANY shall deliver reports to WHITEHEAD annually,
within [***] of the end of each calendar year, containing information concerning the immediately preceding calendar year, as further
described in Section 5.2.

 

(b)                
Upon First Commercial Sale of a LICENSED PRODUCT, DISCOVERED PRODUCT or First Commercial Performance of a LICENSED PROCESS
or LICENSED SERVICE. COMPANY shall report to WHITEHEAD the date of first commercial sale of a LICENSED PRODUCT and. DISCOVERED
PRODUCT and the date of first commercial performance of a LICENSED PROCESS or LICENSED SERVICE within [***] of occurrence in each
country.

 

(c)                 
After First Commercial Sale. After the first commercial sale of a LICENSED PRODUCT or DISCOVERED PRODUCT, or first
commercial performance of a LICENSED PROCESS or LICENSED SERVICE, COMPANY shall deliver reports to WHITEHEAD within [***] of the
end of each REPORTING PERIOD, containing information concerning the immediately preceding REPORTING PERIOD, as further described
in Section 5.2.

 

5.2         
Content of Reports and Payments. Each report delivered by COMPANY to WHITEHEAD shall contain at least the following
information for the immediately preceding REPORTING PERIOD:

 

(i)                  
the number of LICENSED PRODUCTS or DISCOVERED PRODUCTS sold, leased or distributed by COMPANY, its AFFILIATES and SUBLICENSEES
to independent third parties in each country, and, if applicable, the number of LICENSED PRODUCTS or DISCOVERED PRODUCTS used by
COMPANY, its AFFILIATES and SUBLICENSEES in the provision of services in each country as may be pertinent to a royalty accounting
hereunder;

 

(ii)                 
a description of LICENSED PROCESSES and/or LICENSED SERVICES performed by COMPANY, its AFFILIATES and SUBLICENSEES in each
country as may be pertinent to a royalty accounting hereunder;

 

(iii)                 the
gross price charged by COMPANY, its AFFILIATES and SUBLICENSEES for each LICENSED PRODUCT or DISCOVERED PRODUCT and, if
applicable, the gross price charged for each LICENSED PRODUCT or DISCOVERED PRODUCT used to provide services in each; and the
gross price charged for each LICENSED PROCESS or LICENSED SERVICE performed by COMPANY, its AFFILIATES and SUBLICENSEES in
each country as may be pertinent to a royalty accounting hereunder;

 

    -11- 

     

    

 

(iv)               
calculation of NET SALES for the applicable REPORTING PERIOD in each country as may be pertinent to a royalty accounting
hereunder, including a listing of applicable deductions;

 

(v)                 
total royalty payable on NET SALES in U.S. dollars, together with the exchange rates used for conversion;

 

(vi)               
calculation of SERVICE INCOME for the applicable REPORTING PERIOD in each country, and the amount due to WHITEHEAD from
such SERVICE INCOME in U.S. dollars, together with the exchange rates used for conversion.

 

(vii)              
the amount of SUBLICENSE INCOME and CORPORATE PARTNER INCOME received by COMPANY from each SUBLICENSEE and/or CORPORATE
PARTNER and the amount due to WHITEHEAD from such SUBLICENSE INCOME and/or CORPORATE PARTNER INCOME, including an itemized breakdown
of the sources of income comprising the SUBLICENSE INCOME and/or CORPORATE PARTNER INCOME;

 

(viii)             
the number of CORPORATE PARTNER relationships entered into for LICENSED PRODUCTS and/or LICENSED PROCESSES; and

 

(ix)                
the number of sublicenses entered into for the PATENT RIGHTS, LICENSED PRODUCTS, LICENSED PROCESSES, TANGIBLE PROPERTY,
or LICENSED SERVICES.

 

If no amounts are due
to WHITEHEAD for any REPORTING PERIOD, the report shall so state.

 

5.3         
Financial Statements. On or before the [***] following the close of COMPANY’s fiscal year, COMPANY shall provide
WHITEHEAD with COMPANY’s financial statements for the preceding fiscal year including, at a minimum, a balance sheet and
an income statement, certified by COMPANY’s treasurer or chief financial officer or by an independent auditor.

 

5.4         
Records. COMPANY shall maintain, and shall cause its AFFILIATES and SUBLICENSEES to maintain, complete and accurate
records relating to the rights and obligations under this Agreement and any amounts payable to WHITEHEAD in relation to this Agreement,
which records shall contain sufficient information to permit WHITEHEAD to confirm the accuracy of any reports delivered to WHITEHEAD
and compliance in other respects with this Agreement. The relevant party shall retain such records for at least [***] following
the end of the calendar year to which they pertain, during which time WHITEHEAD, or WHITEHEAD ‘s appointed agents, shall
have the right, at WHITEHEAD ‘s expense, to inspect such records during normal business hours to verify any reports and payments
made or compliance in other respects under this Agreement. In the event that any audit performed under this Section reveals an
underpayment in excess of [***], COMPANY shall bear the full cost of such audit and shall remit any amounts due to WHITEHEAD within
[***] of receiving notice thereof from WHITEHEAD.

 

6.                  
PATENT PROSECUTION.

 

6.1         Responsibility
for PATENT RIGHTS. Within a commercially reasonable period following the EFFECTIVE DATE, WHITEHEAD and COMPANY will work
together to prepare provisional filings and/or continuations, for cancelled patent claims, which will be diligently
prosecuted by WHITEHEAD. WHITEHEAD shall diligently prepare, file, prosecute, and maintain all of the PATENT RIGHTS. COMPANY
shall have reasonable opportunities to advise WHITEHEAD and shall cooperate with WHITEHEAD in such filing, prosecution and
maintenance. So long as COMPANY remains a licensee in good standing under the terms and conditions of the Agreement,
WHITEHEAD shall not unreasonably restrict filing of continuation and/or divisional applications requested by COMPANY.
Furthermore, WHITEHEAD shall consult with COMPANY before abandoning any of the PATENT RIGHTS.

 

    -12- 

     

    

 

6.2        
Payment of Expenses. Payment of all fees and costs, including attorneys’ fees, relating to the filing, prosecution
and maintenance of the PATENT RIGHTS shall be the responsibility of COMPANY, whether such amounts were incurred before or after
the EFFECTIVE DATE. As of May29, 2009, WHITHEAD has incurred approximately $23,957 for such unreimbursed patent-related fees and
costs. COMPANY shall reimburse all amounts due pursuant to this Section within thirty (30) days of invoicing; late payments shall
accrue interest pursuant to Section 4.2(c). In all instances, WHITHEAD shall pay the fees prescribed for large entities to the
United States Patent and Trademark Office.

 

7.                  
INFRINGEMENT.

 

7.1        
Notification of Infringement. Each party agrees to provide written notice to the other parties promptly after becoming
aware of any infringement of the PATENT RIGHTS.

 

7.2         
Right to Prosecute Infringements.

 

(a)                 
COMPANY Right to Prosecute. So long as COMPANY remains the exclusive licensee of the PATENT RIGHTS in the FIELD in
the TERRITORY, COMPANY, to the extent permitted by law, shall have the right, under its own control and at its own expense, to
prosecute any third party infringement of the PATENT RIGHTS in the FIELD in the TERRITORY, subject to Sections 7.4 and 7.5. If
required by law, WHITEHEAD or M.I.T. shall permit any action under this Section to be brought in their names, including being joined
as a party-plaintiff, provided that COMPANY shall hold WHITEHEAD and M.I.T. harmless from, and indemnify WHITEHEAD and M.I.T. against,
any costs, expenses, or liability that WHITEHEAD or M.I.T. incurs in connection with such action.

 

Prior to commencing any
such action, COMPANY shall consult with WHITEHEAD and M.I.T. and shall consider the views of WHITEHEAD and M.I.T. regarding the
advisability of the proposed action and its effect on the public interest. COMPANY shall not enter into any settlement, consent
judgment, or other voluntary final disposition of any infringement action under this Section without the prior written consent
of WHITEHEAD and M.I.T.

 

(b)                 
WHITEHEAD Right to Prosecute. In the event that COMPANY is unsuccessful in persuading the alleged infringer to desist
or fails to have initiated an infringement action within a reasonable time after COMPANY first becomes aware of the basis for
such action, WHITEHEAD shall have the right, at its sole discretion, to prosecute such infringement under its sole control and
at its sole expense, and any recovery obtained shall belong to WHITEHEAD.

 

    -13- 

     

    

 

7.3          Declaratory Judgment Actions. In the event that a PATENT CHALLENGE is brought against WHITEHEAD or COMPANY by a
third party, WHITEHEAD, at its option, shall have the right within twenty (20) days after commencement of such action to take
over the sole defense of the action at its own expense. If WHITEHEAD does not exercise this right, COMPANY may take over the sole
defense of the action at COMPANY’s sole expense, subject to Sections 7.4 and 7.5.

 

7.4         
Offsets. COMPANY may offset a total of fifty percent (50%) of any expenses incurred under Sections 7.2 and 7.3 against
any payments due to M.I.T. under Article 4, provided that in no event shall such payments under Article 4, when aggregated with
any other offsets and credits allowed under this Agreement, be reduced by more than fifty percent (50%) in any REPORTING PERIOD.

 

7.5         
Recovery. Any recovery obtained in an action brought by COMPANY under Sections 7.2 or 7.3 shall be distributed as
follows: (i) each party shall be reimbursed for any expenses incurred in the action (including the amount of any royalty or other
payments withheld from M.I.T. as described in Section 7.4), (ii) as to ordinary damages, [***], and (iii) as to special or punitive
damages, the parties shall share as follows:

 

(a)                
[***];

 

(b)                
[***].

 

7.6         
Cooperation. Each party agrees to cooperate in any action under this Article which is controlled by any other party,
provided that the controlling party reimburses the cooperating parties promptly for any costs and expenses incurred by the cooperating
party in connection with providing such assistance.

 

7.7        
Right to Sublicense. So long as COMPANY remains the exclusive licensee of the PATENT RIGHTS in the FIELD in the TERRITORY,
COMPANY shall have the sole right to sublicense any alleged infringer in the FIELD in the TERRITORY for future use of the PATENT
RIGHTS in accordance with the terms and conditions of this Agreement relating to sublicenses. Any upfront fees as part of such
sublicense shall be shared equally between COMPANY and WHITEHEAD; other revenues to COMPANY pursuant to such sublicense shall be
treated as set forth in Article 4.

 

8.                  
INDEMNIFICATION AND INSURANCE

 

8.1         
Indemnification.

 

(a)                
Indemnity. COMPANY shall indemnify, defend, and hold harmless M.I.T., WHITEHEAD and their trustees, officers, faculty,
students, employees, and agents and their respective successors, heirs and assigns (the “Indemnitees”), against any
liability, damage, loss, or expense (including reasonable attorneys’ fees and expenses) incurred by or imposed upon any of
the Indemnitees in connection with any claims, suits, investigations, actions, demands or judgments arising out of or related to
the exercise of any rights granted to COMPANY under this Agreement or any breach of this Agreement by COMPANY.

 

(b)                 Procedures.
The Indemnitees agree to provide COMPANY with prompt written notice of any claim, suit, action, demand, or judgment for which
indemnification is sought under this Agreement. COMPANY agrees, at its own expense, to provide attorneys reasonably
acceptable to M.I.T. and WHITEHEAD to defend against any such claim. The Indemnitees shall cooperate fully with COMPANY in
such defense and will permit COMPANY to conduct and control such defense and the disposition of such claim, suit, or action
(including all decisions relative to litigation, appeal, and settlement); provided, however, that any Indemnitee shall have
the right to retain its own counsel, at the expense of COMPANY, if representation of such Indemnitee by the counsel retained
by COMPANY would be inappropriate because of actual or potential differences in the interests of such Indemnitee and any
other party represented by such counsel. COMPANY agrees to keep M.I.T. and WHITEHEAD informed of the progress in the defense
and disposition of such claim and to consult with M.I.T. and WHITEHEAD with regard to any proposed settlement.

 

    -14- 

     

    

 

8.2         
Insurance. COMPANY shall obtain and carry in full force and effect commercial general liability insurance, including
product liability and errors and omissions insurance which shall protect COMPANY and Indemnitees with respect to events covered
by Section 8.1(a) above. Such insurance (i) shall be issued by an insurer licensed to practice in the Commonwealth of Massachusetts
or an insurer pre-approved by M.I.T. and WHITEHEAD, such approval not to be unreasonably withheld, (ii) shall list M.I.T. and WHITEHEAD
as an additional insured thereunder, (iii) shall be endorsed to include product liability coverage, and (iv) shall require [***]
written notice to be given to M.I.T. prior to any cancellation or material change thereof. The limits of such insurance shall not
be less than [***] per occurrence with an aggregate of [***] for bodily injury including death; [***] per occurrence with an aggregate
of [***] for property damage; and [***] per occurrence with an aggregate of [***] for errors and omissions. In the alternative,
COMPANY may self-insure subject to prior approval of M.I.T. COMPANY shall provide M.I.T. with Certificates of Insurance evidencing
compliance with this Section. COMPANY shall continue to maintain such insurance or self-insurance after the expiration or termination
of this Agreement during any period in which COMPANY or any AFFILIATE or SUBLICENSEE continues (i) to make, use, or sell a product
that was a LICENSED PRODUCT or POLYPEPTIDE under this Agreement or (ii) to perform a service that was a LICENSED PROCESS under
this Agreement, and thereafter for a period of [***].

 

9.                  
NO REPRESENTATIONS OR WARRANTIES

 

EXCEPT AS OTHERWISE
EXPRESSLY SET FORTH IN THIS AGREEMENT, M.I.T. AND WHITEHEAD MAKE NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE PATENT
RIGHTS AND THE TANGIBLE PROPERTY, AND HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT
LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OF
M.I.T. OR WHITEHEAD OR THIRD PARTIES, VALIDITY, ENFORCEABILITY AND SCOPE OF PATENT RIGHTS, WHETHER ISSUED OR PENDING, AND THE ABSENCE
OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE.

 

The TANGIBLE PROPERTY
is experimental in nature and will be used with prudence and appropriate caution, since not all of its characteristics are known.

 

IN NO EVENT SHALL
M.I.T. AND WHITEHEAD AND THEIR RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR INCIDENTAL OR
CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGES OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER
M.I.T. OR WHITEHEAD SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE
FOREGOING.

 

    -15- 

     

    

 

10.               
ASSIGNMENT.

 

This Agreement is personal
to COMPANY and no rights or obligations may be assigned by COMPANY without the prior written consent of M.I.T. Any such assignment
shall be void. Notwithstanding the foregoing, COMPANY may assign and delegate all its rights and obligations under this Agreement
to any entity to which COMPANY sells or transfers all or substantially all of its assets or with which it merges or consolidates,
provided that, upon such assignment, merger, or purchase, [***] and (ii) that this Agreement will immediately terminate
if the assignee has not agreed in writing prior to such assignment to be bound by all of the terms and conditions of this Agreement.

 

11.               
GENERAL COMPLIANCE WITH LAWS

 

11.1       
Compliance with Laws. COMPANY shall use reasonable commercial efforts to comply with all commercially material local,
state, federal, and international laws and regulations relating to the development, manufacture, use, and sale of LICENSED PRODUCTS,
POLYPEPTIDES, TANGIBLE PROPERTY, and LICENSED PROCESSES. COMPANY will use the TANGIBLE PROPERTY in compliance with all laws, governmental
regulations and guidelines, including current National Institutes of Health guidelines and any regulations or guidelines pertaining
to research with animals or recombinant DNA, that may be applicable to the TANGIBLE PROPERTY.

 

11.2       
Export Control. COMPANY and its AFFILIATES and SUBLICENSEES shall comply with all United States laws and regulations
controlling the export of certain commodities and technical data, including without limitation all Export Administration Regulations
of the United States Department of Commerce. Among other things, these laws and regulations prohibit or require a license for the
export of certain types of commodities and technical data to specified countries. COMPANY hereby gives written assurance that it
will comply with, and will cause its AFFILIATES and SUBLICENSEES to comply with, all United States export control laws and regulations,
that it bears sole responsibility for any violation of such laws and regulations by itself or its AFFILIATES or SUBLICENSEES, and
that it will indemnify, defend, and hold M.I.T. and WHITEHEAD harmless (in accordance with Section 8.1) for the consequences of
any such violation.

 

11.3       Non-Use
of M.I.T. Name. COMPANY and its AFFILIATES and SUBLICENSEES shall not use the name of “Massachusetts Institute of
Technology,” “Lincoln Laboratory,” “Whitehead Institute” or any variation, adaptation, or
abbreviation thereof, or of any of its trustees, officers, faculty, students, employees, or agents, or any trademark owned by
M.I.T., or any terms of this Agreement in any promotional material or other public announcement or disclosure without the
prior written consent of M.I.T, which consent M.I.T. may withhold in its sole discretion. The foregoing notwithstanding,
without the consent of M.I.T., COMPANY may make factual statements during the term of this Agreement that COMPANY has a
license from M.I.T. under one or more of the patents and/or patent applications comprising the PATENT RIGHTS.

 

    -16- 

     

    

 

11.4       
Marking of LICENSED PRODUCTS. To the extent commercially feasible and consistent with prevailing business practices,
COMPANY shall mark, and shall cause its AFFILIATES and SUBLICENSEES to mark, all LICENSED PRODUCTS and POLYPEPTIDES that are manufactured
or sold under this Agreement with the number of each issued patent under the PATENT RIGHTS that applies to such LICENSED PRODUCT
and POLYPEPTIDE.

 

12.               
TERMINATION

 

12.1       
Voluntary Termination by COMPANY. COMPANY shall have the right to terminate this Agreement, for any reason, (i) upon
at least [***] prior written notice to M.I.T., such notice to state the date at least [***] in the future upon which termination
is to be effective, and (ii) upon payment of all amounts due to M.I.T. or WHITEHEAD through such termination effective date.

 

12.2       
Cessation of Business. If COMPANY ceases to carry on its business related to this Agreement, M.I.T. shall have the
right to terminate this Agreement immediately upon written notice to COMPANY.

 

12.3       
Termination for Default.

 

(a)                 
Nonpayment. In the event COMPANY fails to pay any amounts due and payable to M.I.T. or WHITHEAD hereunder, and fails
to make such payments within [***] after receiving written notice of such failure, M.I.T. may terminate this Agreement immediately
upon written notice to COMPANY.

 

(b)                
Material Breach. In the event COMPANY commits a material breach of its obligations under this Agreement, except for
breach as described in Section 12.3(a), and fails to cure that breach within [***] after receiving written notice thereof, M.I.T.
may terminate this Agreement immediately upon written notice to COMPANY.

 

12.4       
Termination as a Consequence of PATENT CHALLENGE.

 

(a)                 
By COMPANY. If COMPANY or any of its AFFILATES brings a PATENT CHALLENGE against WHITEHEAD, or assists others in
bringing a PATENT CHALLENGE against WHTEHEAD (except as required under a court order or subpoena), then M.I.T. may immediately
terminate this Agreement.

 

(b)                
By SUBLICENSEE. If a SUBLICENSEE brings a PATENT CHALLLENGE or assists another party in bringing a PATENT CHALLENGE
(except as required under a court order or subpoena), then M.I.T. may send a written demand to COMPANY to terminate such sublicense.
If COMPANY fails to so terminate such sublicense within [***] after M.I.T.’s demand, M.I.T. may immediately terminate this
Agreement.

 

12.5       
Effect of Termination.

 

(a)                 
Survival. The following provisions shall survive the expiration or termination of this Agreement: Articles 1, 8,
9, 13 and 14, and Sections 4.1(c)(ii), 4.1(c)(iii), 4.1(d), 4.1(k), 5.2 (obligation to provide final report and payment), 5.4,
11.1, 11.2 and 12.5.

 

    -17- 

     

    

 

(b)                 Inventory. Upon the early termination of this Agreement, COMPANY and its AFFILIATES and SUBLICENSEES may complete
and sell any work-in-progress and inventory of LICENSED PRODUCTS and/or POLYPEPTIDES that exist as of the effective date of termination,
provided that (i) COMPANY pays M.I.T. the applicable running royalty or other amounts due on such sales of LICENSED PRODUCTS and/or
POLYPEPTIDES in accordance with the terms and conditions of this Agreement, and (ii) COMPANY and its AFFILIATES and SUBLICENSEES
shall complete and sell all work-in-progress and inventory of LICENSED PRODUCTS and/or POLYPEPTIDES within [***] after the effective
date of termination.

 

(c)                  Pre-termination
Obligations. In no event shall termination of this Agreement release COMPANY, AFFILIATES, or SUBLICENSEES from the obligation
to pay any amounts that became due on or before the effective date of termination.

   

(d)                
TANGIBLE PROPERTY. Upon termination, COMPANY shall destroy all TANGIBLE PROPERTY. COMPANY shall confirm such destruction
in writing.

 

13.               
DISPUTE RESOLUTION.

 

13.1       
Mandatory Procedures. The parties agree that any dispute arising out of or relating to this Agreement shall be resolved
solely by means of the procedures set forth in this Article, and that such procedures constitute legally binding obligations that
are an essential provision of this Agreement. If any party fails to observe the procedures of this Article, as may be modified
by their written agreement, the other parties may bring an action for specific performance of these procedures in any court of
competent jurisdiction.

 

13.2       
Equitable Remedies. Although the procedures specified in this Article are the sole and exclusive procedures for the
resolution of disputes arising out of or relating to this Agreement, any party may seek a preliminary injunction or other provisional
equitable relief if, in its reasonable judgment, such action is necessary to avoid irreparable harm to itself or to preserve its
rights under this Agreement.

 

13.3       
Dispute Resolution Procedures.

 

(a)                 
Mediation. In the event any dispute arising out of or relating to this Agreement remains unresolved within [***]
from the date the affected party informed the other parties of such dispute, any party may initiate mediation upon written notice
to the other party (“Notice Date”), whereupon all parties shall be obligated to engage in a mediation proceeding under
the then current Center for Public Resources (“CPR”) Model Procedure for Mediation of Business Disputes (http://www.cpradr.org),
except that specific provisions of this Article shall override inconsistent provisions of the CPR Model Procedure. The mediator
will be selected from the CPR Panels of Neutrals. If the parties cannot agree upon the selection of a mediator within [***] after
the Notice Date, then upon the request of any party, the CPR shall appoint the mediator. The parties shall attempt to resolve the
dispute through mediation until the first of the following occurs: (i) the parties reach a written settlement; (ii) the mediator
notifies the parties in writing that they have reached an impasse; (iii) the parties agree in writing that they have reached an
impasse; or (iv) the parties have not reached a settlement within [***] after the Notice Date.

 

(b)                
[***]

 

    -18- 

     

    

 

13.4            
 Performance to Continue. Each party shall continue to perform its undisputed obligations under this Agreement pending
final resolution of any dispute arising out of or relating to this Agreement; provided, however, that a party may suspend performance
of its undisputed obligations during any period in which any other party fails or refuses to perform its undisputed obligations.
Nothing in this Article is intended to relieve COMPANY from its obligation to make undisputed payments pursuant to Articles 4 and
6 of this Agreement.

 

13.5            
Statute of Limitations. The parties agree that all applicable statutes of limitation and time-based defenses (such
as estoppel and laches) shall be tolled while the procedures set forth in Sections 13.3(a) are pending. The parties shall cooperate
in taking any actions necessary to achieve this result.

 

14.               
MISCELLANEOUS.

 

14.1            
Notice. Any notices required or permitted under this Agreement shall be in writing, shall specifically refer to this
Agreement, and shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, confirmed electronic
mail, or registered or certified mail, postage prepaid, return receipt requested, to the following addresses or facsimile numbers
of the parties:

 

If to M.I.T., all matters
relating to the license:

 

Massachusetts Institute of Technology

Technology Licensing Office, Rm NE25-230

Five Cambridge Center, Kendall Square

Cambridge, MA 02142-1493

Attention: Director

Tel:               [***]

Fax:               [***]

 

If to M.I.T., relating
to any EQUITY action after the initial issuance of shares:

 

Massachusetts Institute of Technology

Treasurer’s Office

238 Main Street

Cambridge, MA 02142

Attention:    [***]

Tel:               [***]

Fax:               [***]

 

If to WHITEHEAD.:

 

Whitehead Institute for Biomedical Research

Nine Cambridge Center

Cambridge, MA 02142

Attention: Intellectual Property Office

Tel:               [***]

Fax:               [***]

 

    -19- 

     

    

 

If to COMPANY:

 

[***]

Immunome, Inc.
[***]

Wynnewood, PA 19096

Attention:    [***]

Phone:          [***]

Fax:              [***]

 

If, to COMPANY, notices
regarding financial matters, including invoices:

 

Immunome, Inc.

[***]

Wynnewood, PA 19096

Attention:    [***]

Phone:          [***]

Fax:               [***]

 

All notices under this
Agreement shall be deemed effective upon receipt. A party may change its contact information immediately upon written notice to
the other parties in the manner provided in this Section.

 

14.2       
Governing Law/Jurisdiction. This Agreement and all disputes arising out of or related to this Agreement, or the performance,
enforcement, breach or termination hereof, and any remedies relating thereto, shall be construed, governed, interpreted and applied
in accordance with the laws of the Commonwealth of Massachusetts, U.S.A., without regard to conflict of laws principles, except
that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent
shall have been granted. The state and federal courts having jurisdiction over Cambridge, MA, USA, provide the exclusive forum
for any PATENT CHALLENGE and/or any court action between the parties relating to this Agreement. COMPANY submits to the jurisdiction
of such courts and waives any claim that such court lacks jurisdiction over COMPANY or its AFFILIATES or constitutes an inconvenient
or improper forum.

 

14.3       
Force Majeure. No party will be responsible for delays resulting from causes beyond the reasonable control of such
party, including without limitation fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially
reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with reasonable
dispatch whenever such causes are removed.

 

14.4       
Amendment and Waiver. This Agreement may be amended, supplemented, or otherwise modified only by means of a written
instrument signed by all parties. Any waiver of any rights or failure to act in a specific instance shall relate only to such instance
and shall not be construed as an agreement to waive any rights or fail to act in any other instance, whether or not similar.

 

14.5      
Severability. In the event that any provision of this Agreement shall be held invalid or unenforceable for any reason,
such invalidity or unenforceability shall not affect any other provision of this Agreement, and the parties shall negotiate in
good faith to modify the Agreement to preserve (to the extent possible) their original intent. If the parties fail to reach a modified
agreement within [***] after the relevant provision is held invalid or unenforceable, then the dispute shall be resolved in accordance
with the procedures set forth in Article 13. While the dispute is pending resolution, this Agreement shall be construed as if such
provision were deleted by agreement of the parties.

 

    -20- 

     

    

 

14.6        Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
permitted successors and assigns.

 

14.7       
Headings. All headings are for convenience only and shall not affect the meaning of any provision of this Agreement.

 

14.8       
Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to its subject
matter and supersedes all prior agreements or understandings between the parties relating to its subject matter.

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be executed by their duly authorized representatives.

 

The EFFECTIVE DATE
of this Agreement is June 25, 2009          

 

	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	 	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
	 	 	 
	By:	/s/ Lita Nelsen	 	By:	/s/ Martin Mullins
	 	 	 	 	 
	Name: 	Lita L. Nelsen	 	Name: 	Martin Mullins
	 	 	 	 	 
	Title:	Director Technology Licensing Office	 	Title:	Vice President

 

	IMMUNOME,
    INC.	 
	 	 
	By:	/s/
    Scott Dessain	 
	 	 	 
	Name: 	Scott
    Dessain	 
	 	 	 
	Title:	C.E.O.	 

 

    -21- 

     

    

 

APPENDIX A

List of Patent Applications and Patents

 

[***]

  

    -22- 

     

    

 

APPENDIX B

TANGIBLE PROPERTY 

 

[***]

 

    -23- 

     

    

 

FIRST AMENDMENT TO THE EXCLUSIVE
PATENT LICENSE AGREEMENT

 

This First Amendment, effective as of December 17, 2009 (the
 “AMENDMENT EFFECTIVE DATE”), is among the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts
corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307, the Whitehead Institute for Biomedical
Research (“WHITEHEAD”), a Delaware corporation, with a principal office at Nine Cambridge Center, Cambridge, Massachusetts
02142, and Immunome, Inc. (“COMPANY”), a Pennsylvania corporation, with a principal place of business at 100 Lancaster
Avenue, Wynnewood, PA 19096.

 

WHEREAS, M.I.T., WHITEHEAD, and COMPANY entered into an Exclusive
Patent License Agreement dated June 25, 2009 (the “LICENSE”);

 

WHEREAS, M.I.T., WHITEHEAD, and COMPANY desire to amend the
provisions of the LICENSE upon the terms and conditions hereinafter set forth.

 

NOW, THEREFORE, M.I.T., WHITEHEAD, and COMPANY hereby agree
as follows:

 

1.       Section 6.2 of the
LICENSE reads as follows:

 

6.2       Payment
of Expenses. Payment of all fees and costs, including attorneys’ fees, relating to the filing, prosecution and maintenance
of the PATENT RIGHTS shall be the responsibility of COMPANY, whether such amounts were incurred before or after the EFFECTIVE DATE.
As of May 29, 2009, WHITHEAD [sic] has incurred approximately $23,957 for such unreimbursed patent-related fees and costs.
COMPANY shall reimburse all amounts due pursuant to this Section within [***] of invoicing; late payments shall accrue interest
pursuant to Section 4.2(c). In all instances, WHITHEAD [sic] shall pay the fees prescribed for large entities to the United
States Patent and Trademark Office.

 

Section 6.2 will be deleted in its entirety and replaced with
the following:

 

6.2       Payment
of Expenses. Payment of all fees and costs, including attorneys’ fees, relating to the filing, prosecution and maintenance
of the PATENT RIGHTS shall be the responsibility of COMPANY, for such amounts incurred on or after October 31, 2009. For patent
expenses incurred prior to May 29, 2009, the Company shall be obligated to pay no more than $23,957.00 for unreimbursed patent
expenses for the PATENT RIGHTS. For patent expenses incurred on or after May 29, 2009 and through October 31, 2009, the Company
shall be obligated to pay no more than $5,229.80 for unreimbursed patent expenses for the PATENT RIGHTS.

 

As of the AMENDMENT EFFECTIVE DATE, WHITEHEAD has
received $13,692.60 from COMPANY for such unreimbursed patent-related fees and costs incurred prior to May 29, 2009, and COMPANY
shall pay the balance of unreimbursed patent expenses prior to May 29, 2009 ($10,264.40) and patent expenses incurred on or after
May 29, 2009 and through October 31, 2009 ($5,229.80) which totals $15,494.20 as follows:

 

(a) $5,494.20 on the signing of this First Amendment;
and

(b) $10,000 on December 7, 2010.

 

     

     

    

 

Termination of the LICENSE for any reason does not
remove Company’s obligation to pay the amounts specified in (a) and (b) above.

 

COMPANY shall reimburse all amounts due for the period
after October 31, 2009 pursuant to this Section within [***] of invoicing; late payments shall accrue interest pursuant to Section
4.2(c). In all instances, WHITEHEAD shall pay the fees prescribed for large entities to the United States Patent and Trademark
Office.

 

2.       The LICENSE, as
amended hereby, is hereby ratified and confirmed in all respects and shall continue in full force and effect. The LICENSE shall,
together with this First Amendment, be read and construed as a single instrument. All other terms and conditions of the LICENSE
are confirmed and remain in full force and effect. This First Amendment shall be binding upon, and shall inure to the benefit of,
the parties hereto and their respective successors and assigns.

 

IN WITNESS WHEREOF, the parties have caused this First Amendment
to be executed by their duly authorized representatives.

 

	MASSACHUSETTS
    INSTITUTE OF TECHNOLOGY	 	WHITEHEAD
    INSTITUTE FOR BIOMEDICAL RESEARCH 
	 	 	 
	By:	 /s/ Lita L. Nelsen 	 	By:	 /s/ Martin A. Mullins 
	Name: 	Lita L. Nelsen 	 	Name: 	Martin A. Mullins 
	Title:	 Director, Technology Licensing Office	 	Title: 	Vice President
	 	 	 	 	 
	IMMUNOME, INC. 	 	 
	 	 	 
	By:	 /s/ Timothy J. Pelura 	 	 
	Name:	 Timothy J. Pelura	 	 
	Title:	 President & CEO	 	 

 

    

     

    

 

SECOND AMENDMENT TO

EXCLUSIVE PATENT LICENSE AGREEMENT

 

This SECOND AMENDMENT
TO EXCLUSIVE PATENT LICENSE AGREEMENT (this “Amendment”) dated as of March 21, 2013 by and among the Massachusetts
Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue,
Cambridge, MA 02139-4307, the Whitehead Institute for Biomedical Research (“Whitehead”), a Delaware corporation, with
a principal office at Nine Cambridge Center, Cambridge, Massachusetts 02142, and Immunome, Inc. (the “Company”), a
Pennsylvania corporation, with a principal place of business at 100 Lancaster Avenue, Wynnewood, PA 19096.

 

Recitals:

 

The parties entered
into an Exclusive Patent License Agreement effective as of June 25, 2009. and first amended effective as of December 17, 2009 (the
 “License Agreement”), pursuant to which M.I.T., as agent of Whitehead, granted to the Company a license under the Patent
Rights and a license to use the Tangible Property to develop, make, have made, use, sell, offer to sell, lease and import Licensed
Products in the Field in the Territory and to develop and perform Licensed Processes and perform Licensed Services in the Field
in the Territory. Capitalized terms used in this .Amendment without definition shall have the respective, meanings assigned to
them in the License Agreement.

 

Pursuant to the License
Agreement, the Company agreed to pay to Whitehead certain license maintenance fees. The parties have agreed that such license maintenance
fees shall be reduced. Accordingly, the parties are entering into this Amendment to memorialize such agreement.

 

NOW, THEREFORE, in
consideration of the premises and covenants set forth herein, and intending to be legally bound hereby, the parties hereto agree
as follows:

 

1.                
Amendment to Section 4.1(b). Section 4.1(b) of the License Agreement is hereby amended and restated in its entirety
so as to provide as follows:

 

(b)       License
Maintenance Fees. COMPANY shall pay to WHITEHEAD the following license maintenance fees on the dates set forth below:

 

	 	[***]	[***]
	 	[***]	[***]
	 	[***]	[***]
	 	[***]	[***]
	 	[***]	[***]
	 	[***]	[***]
	 	[***]	[***]
	 	[***]	[***]
	 	[***]	[***]
	 	and each January 1st of every year thereafter during the TERM.	 

 

     

     

    

 

This annual license
maintenance fee is nonrefundable; however, the license maintenance fee may be credited to running royalties subsequently due on
NET SALES and SERVICE INCOME earned during the same calendar year, if an. License maintenance fees paid in excess of running royalties
due in such calendar year shall not be creditable to amounts due for future years.

 

2.                 
Effect of Amendment. The parties acknowledge and agree that all of the terms, provisions, covenants and conditions of
the License Agreement shall hereafter continue in full force and effect in accordance with the terms thereof, except to the extent
amended herein.

 

3.                 
Governing Law. This Amendment and all disputes arising out of or relating hereto shall be governed by and construed
under the laws of the Commonwealth of Massachusetts, without giving effect to the principles of conflicts of laws.

 

4.                 
Counterparts. This Agreement may be executed in one or more counterparts with the same effect as if all of the parties
had signed the same document. All counterparts shall be construed together and shall constitute one and the same instrument. Executed
counterparts of this Agreement may be delivered by electronic or facsimile transmission with the same effect. as if delivered personally.

 

 

IN WITNESS WHEREOF,
the parties have caused this Amendment to be executed as of the date first written above.

 

	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	 	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
	 	 	 
	By: 	/s/ Lita L. Nelson	 	By:	 /s/ Carla DeMaria
	 	 	 
	Title: 	Director Technology Licensing Office	 	Title:	 4-3-13 Director of IP & Sponsored Programs
	 	 	 
	IMMUNOME. INC.	 	 
	 	 	 
	Name: 	/s/ T.J. Pelura	 	 
	 	 	 
	Title: 	President and CEO	 	 
	 	 	 

 

    2

     

    

 

THIRD AMENDMENT TO

EXCLUSIVE PATENT LICENSE AGREEMENT

 

This THIRD AMENDMENT TO EXCLUSIVE PATENT
LICENSE AGREEMENT (this “Third Amendment”) dated as of August 21, 2017 (the “Third Amendment Effective Date”),
by and between Whitehead Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, with a principal
office at 455 Main Street, Cambridge, Massachusetts 02142, and Immunome, Inc. (the “COMPANY”), a Delaware corporation,
with a principal place of business at 665 Stockton Drive, Suite 300, Exton, PA 19341.

 

Recitals:

 

WHEREAS, WHITEHEAD, COMPANY, and Massachusetts
Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue,
Cambridge, MA 02139-4307 entered into an Exclusive Patent License Agreement effective as of June 25, 2009, and first amended effective
as of December 17, 2009, and second amended effective March 21, 2013 (the “License Agreement”; Whitehead Ref: L4417;
L4579; L5806);

 

WHEREAS, M.I.T. is no longer acting as WHITEHEAD’s
agent for the purpose of licensing the PATENT RIGHTS, and M.I.T. does not need to-be a party to this Third Amendment;

 

WHEREAS, pursuant to the License Agreement,
COMPANY and WHITEHEAD agreed to certain diligence obligations and sharing of sublicense income. The parties have agreed to restate
the diligence obligations and reduce the sublicense income rate. Accordingly, the parties are entering into this Amendment to memorialize
such agreement; and

 

WHEREAS, capitalized terms used in this
Third Amendment without definition will have the respective meanings assigned to them in the License Agreement.

 

NOW, THEREFORE, in consideration of the
premises and covenants set forth herein, and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.       Amendment
to Section 3.1. Section 3.1 of the License Agreement is hereby amended and restated in its entirety so as to provide as follows:

 

3.1 Diligence Requirements. COMPANY shall use
diligent efforts, or shall cause its AFFILIATES and SUBLICENSEES to use diligent efforts, to develop LICENSED PRODUCTS or LICENSED
PROCESSES and to introduce LICENSED PRODUCTS or LICENSED PROCESSES into the commercial market; thereafter, COMPANY or its AFFILIATES
or SUBLICENSEES shall make LICENSED PRODUCTS or LICENSED PROCESSES reasonably available to the public.

 

    

     

    

 

Specifically, COMPANY or AFFILIATE
or SUBLICENSEE shall fulfill the following obligations:

 

(a) [***]

 

(b) [***]

 

(c) [***]

 

(d) [***]

 

(e) [***]

 

(f) [***]

 

(g) [***]

 

(h) [***]

 

(i) [***]

 

(j) [***]

 

(k) [***]

 

(l) [***]

 

In the event that COMPANY,
AFFILIATE, or SUBLICENSEE, has not performed one or more of Sections 3.1(a) through (1), and such failure is because of a
bona fide and documented scientific, technical, or regulatory issue which is communicated to WHITEHEAD, then such
non-performance shall not constitute a breach of this Agreement, and instead WHITEHEAD and COMPANY shall negotiate in good
faith a reasonable extension of time for COMPANY, AFFILIATE, or SUBLICENSEE to achieve the specific obligation and WHITEHEAD
shall not unreasonably deny or condition such extension. If the parties are unable to agree on the length of such extension
of time, then the matter shall be resolved in accordance with Section 13.3 (Dispute Resolution Procedures). For the avoidance
of doubt, any obligation on the part of COMPANY or any AFFILIATE or SUBLICENSEE to comply with Sections 3.1(a) through (1)
prior to the THIRD AMENDMENT EFFECTIVE DATE is hereby waived.

 

    2

     

    

 

2.       Amendment
to Section 4.1(g). Section 4.1(g) of the License Agreement is hereby amended and restated in its entirety so as to provide
as follows:

 

(g)       SUBLICENSE
INCOME.

 

(i)       Sharing
of SUBLICENSE INCOME. Subject to Section 2.3, in the event COMPANY or an AFFILIATE grants a sublicense of its rights under
Section 2.1 for a specified LICENSED PRODUCT, COMPANY shall pay WHITEHEAD a total of [***] of all SUBLICENSE INCOME received by
COMPANY or AFFILIATES from SUBLICENSEES.

 

(ii)      Bundling of PATENT RIGHTS. Notwithstanding
the foregoing, if, in any sublicense of the PATENT RIGHTS for a specified LICENSED PRODUCT, COMPANY or an AFFILIATE also grants
to the SUBLICENSEE rights to other patents owned or controlled by [***].

 

For purposes of this subsection, SUBLICENSE
INCOME will include the total amount of any payments received by COMPANY or an AFFILIATE from a SUBLICENSEE under any such BUNDLED
SUBLICENSE, whether or not specifically related to the PATENT RIGHTS. Such SUBLICENSE INCOME will not be subject to any adjustment
to apportion value to a particular subset of patent rights within any such BUNDLED SUBLICENSE. COMPANY agrees to share [***] of
the total payments under the BUNDLED SUBLICENSE in exchange for: [***].

 

Any amounts due pursuant Section 4.1(g)
will be payable for each REPORTING PERIOD and will be due to WHITEHEAD within [***] of the end of each REPORTING PERIOD.

 

(iii)       Commercially
Reasonable Consideration. Non-monetary consideration shall not be accepted by COMPANY or an AFFILIATE for any sublicense of
the PATENT RIGHTS without the prior written consent of WHITEHEAD, which shall not be unreasonably withheld or delayed. Consideration
for any and all sublicenses of the PATENT RIGHTS shall be on commercially reasonable terms and conditions consistent with amounts
paid for similar technology in the industry.

 

3.       Amendment
to Parties. WHITEHEAD hereby confirms to COMPANY that M.I.T. is no longer acting as WHITEHEAD’s agent for the purpose
of licensing the PATENT RIGHTS, and that M.I.T. therefore is no longer a party to the License Agreement and does not need to-be
a party to this Third Amendment.

 

    3

     

    

 

4.       Effect
of Amendment. The parties acknowledge and agree that all of the terms, provisions, covenants, and conditions of the License
Agreement shall hereafter continue in full force and effect in accordance with the terms thereof, except to the extent amended
herein.

 

5.       Governing
Law. This Third Amendment and the License Agreement and all disputes arising out of or relating hereto shall be governed by
and construed under the laws of the Commonwealth of Massachusetts, without giving effect to the principles of conflicts of laws.

 

6.       Counterparts.
This Third Amendment may be executed in one or more counterparts with the same effect as if all of the parties had signed the same
document. All counterparts shall be construed together and shall constitute one and the same instrument. Executed counterparts
of this Third Amendment may be delivered by electronic transmission with the same effect as if delivered personally.

 

IN WITNESS WHEREOF, this Third Amendment has been duly executed
by the parties hereto as of and on the date first above written.

 

	For WHITEHEAD	 	For COMPANY:
	 	 	 
	By: 	/s/ Carla DeMaria	 	By: 	/s/ Michael J. Morin
	 	 	 
	Name:  	Carla DeMaria	 	Name:  	Michael J. Morin, PhD
	 	 	 
	Title:	Director of Intellectual Property & Sponsored Programs	 	Title:	CEO
	 	 	 	 
	Date:	9/11/17	 	Date: 	29 Aug 2017

 

    4

     

    

 

FOURTH AMENDMENT TO

EXCLUSIVE PATENT LICENSE AGREEMENT

 

This FOURTH AMENDMENT TO EXCLUSIVE PATENT
LICENSE AGREEMENT (this “Fourth Amendment”) dated as of July 21, 2020 (the “Fourth Amendment Effective Date”),
by and between Whitehead Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, with a principal
office at 455 Main Street, Cambridge, Massachusetts 02142, and Immunome, Inc. (the “COMPANY”), a Delaware corporation,
with a principal place of business at 665 Stockton Drive, Suite 300, Exton, PA 19341.

 

Recitals:

 

WHEREAS, WHITEHEAD and COMPANY entered into
an Exclusive Patent License Agreement effective as of June 25, 2009, and first amended effective as of December 17, 2009, and second
amended effective March 21, 2013; and third amended effective August 21, 2017 (the “License Agreement”; Whitehead Ref:
L4417; L4579; L5806; L7208);

 

WHEREAS, pursuant to the License Agreement,
COMPANY and WHITEHEAD agreed to certain royalties. The parties have agreed to restate the royalty structure for sales by a sublicensee
under an agreement between COMPANY and such SUBLICENSEE entered into before clinical proof of concept. Accordingly, the parties
are entering into this Amendment to memorialize such agreement; and

 

WHEREAS, capitalized terms used in this
Fourth Amendment without definition will have the respective meanings assigned to them in the License Agreement.

 

NOW, THEREFORE, in consideration of the
premises and covenants set forth herein, and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.       Amendment
to Section 4.1(b). Section 4.1(b) of the License Agreement is hereby amended and restated in its entirety so as to provide
as follows:

 

(b)       License
Maintenance Fees. COMPANY shall pay to WHITEHEAD the following license maintenance fees on the dates set forth below:

 

January
1, 2021 and each January 1st of every year thereafter during the TERM: [***].

 

This annual
license maintenance fee is nonrefundable; however, the license maintenance fee may be credited to running royalties subsequently
due on NET SALES and SERVICE INCOME earned during the same calendar year, if any. License maintenance fees paid in excess of running
royalties due in such calendar year shall not be creditable to amounts due for future years.

 

     

     

    

 

2.       Amendment
to Section 4.1(d). Section 4.1(d) of the License Agreement is amended to add the following Subsection 4.1(d)(vi):

 

(vi)       Notwithstanding
Section 4.1(d)(i)-(v), the royalty for NET SALES of LICENSED PRODUCTS, LICENSED PROCESSES and DISCOVERED PRODUCTS by any SUBLICENSEE
under an agreement between COMPANY and such SUBLICENSEE entered into before clinical proof of concept with respect to any LICENSED
PRODUCT, LICENSED PROCESS, or DISCOVERED PRODUCT (“OTHER NET SALES”) shall be [***] of the royalty actually paid by
the SUBLICENSEE to COMPANY. Accordingly, for purposes of calculating the royalties under Section 4.1(d)(i)-(v), OTHER NET SALES
shall be disregarded and excluded from the definition of NET SALES. In addition, for purposes of calculating royalties under this
Section 4.1(d)(vi), the Royalty Offset provisions of Section 4.1(e) shall not apply.

 

		3.	Effect of Amendment. The parties acknowledge and agree that all of the terms, provisions, covenants, and conditions
of the License Agreement shall hereafter continue in full force and effect in accordance with the terms thereof, except to the
extent amended herein.

 

		4.	Governing Law. This Fourth Amendment and the License Agreement and all disputes arising out of or relating hereto shall
be governed by and construed under the laws of the Commonwealth of Massachusetts, without giving effect to the principles of conflicts
of laws.

 

		5.	Counterparts. This Fourth Amendment may be executed in one or more counterparts with the same effect as if all of the
parties had signed the same document. All counterparts shall be construed together and shall constitute one and the same instrument.
Executed counterparts of this Fourth Amendment may be delivered by electronic transmission with the same effect as if delivered
personally.

 

[Signatures follow on
the next page.]

  

    2

     

    

 

IN WITNESS WHEREOF, this Fourth Amendment has been duly executed
by the parties hereto as of and on the date first above written.

 

	For WHITEHEAD	 	For COMPANY:
	 	 	 
	By:	/s/ Carla DeMaria	 	By:	 /s/ Purnanand D. Sarma
	 	 	 
	Name:  	Carla DeMaria	 	Name:  	Purnanand D. Sarma
	 	 	 
	Title:	Director of Intellectual Property & Sponsored Programs	 	Title:	President & CEO
	 	 	 
	Date:	7/21/20	 	Date:	 21 July 2020
	 	 	 

 

    3Exhibit 10.16

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED
THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY
DISCLOSED.

 

Exclusive License Agreement

 

Between

 

Thomas Jefferson University (TJU)

 

And

 

Immunome, Inc. (LICENSEE)

 

Effective as of June 1, 2012

 

		Re:	[***]

 

For and in consideration
of the mutual promises and covenants set forth below, the parties, intending to be legally bond, hereto agree as follows:

 

Article
I

DEFINITIONS

 

As used in this Agreement,
the following terms shall have the following meanings:

 

		1.1	ACADEMIC RESEARCH PURPOSES: use of PATENT RIGHTS, or KNOW-HOW, or MATERIALS, or the combination
of the above, for internal, educational, academic, non-commercial and non-commercially sponsored research purposes on a non-transferable
and non-sublicenseable basis or other not-for-profit scholarly purposes which are undertaken at a non-profit or governmental institution
that does not use the PATENT RIGHTS, or KNOW-HOW, or MATERIALS, or the combination of the above, in the production or manufacture
of products for any clinical study or commercial sale or the performance of services for a fee.

 

		1.2	AFFILIATE: shall mean any entity which controls, is controlled by, or is under common control with
LICENSEE. For the purposes of this definition, “control” shall mean beneficial ownership (direct or indirect) of more
than fifty percent (50%) of the shares of the subject entity entitled to vote in the election of directors (or, in the case of
an entity that is not a corporation, for the election of the corresponding managing authority). Unless otherwise specified, the
term LICENSEE includes AFFILIATES.

 

		1.3	CONSIDERATION: shall mean and include without limitation, money, services, property and any other
thing of value such as payment of costs, cancellation or forgiveness of indebtedness, discounts, stocks, rebates, barter and the
like. If any such CONSIDERATION is in a form other than cash (such as in kind, equity interests, indebtedness earn-outs, or other
deferred payments, consulting fees, etc.) then the value of such CONSIDERATION shall be determined in good faith by the Parties.

 

		1.4	FIELD: all fields of use.

 

		1.5	KNOW-HOW: any unpatentable or to be patented developments, applied technical knowledge, ideas,
know-how, information, methods, data, processes, designs, concepts or techniques only known to TJU and is necessary or useful for
the practice of any invention in PATENT RIGHTS which (a) are believed not to be generally known or used in the relevant business
community, (b) if they were disclosed by TJU to a given company, would likely provide such company with an advantage over its competitors;
and (c) which results from research in TJU inventors’ laboratories.

 

     Page 1 of 14

     

    

 

		1.6	LICENSED PROCESSES: the processes covered by at least one VALID CLAIM included within the PATENT
RIGHTS and/or processes made using KNOW-HOW and/or MATERIALS within the FIELD.

 

		1.7	LICENSED PRODUCTS: products covered by at least one VALID CLAIM included within the PATENT RIGHTS,
and/or products made or services provided using LICENSED PROCESSES, and/or products made using KNOW-HOW and/or MATERIALS, and/or
products incorporate MATERIALS within the FIELD.

 

		1.8	LICENSEE: Immunome, Inc., a corporation organized under the laws of Pennsylvania and having a principle
place of business at 100 East Lancaster Avenue, LIMR Building, Room #222, Wynnewood, PA 19096.

 

		1.9	MATERIALS: any biological materials disclosed in the invention disclosures listed in Appendix A
and created by TJU prior to the effective date of this Agreement.

 

		1.10	NET RESEARCH AND DEVELOPMENT INCOME: [***].

 

		1.11	NET SALES: [***], less:

 

		(a)	[***];

 

		(b)	[***];

 

		(c)	[***]; and

 

		(d)	[***].

 

[***]

 

		1.12	NON-ROYALTY SUBLICENSE INCOME: [***].

 

		1.13	PATENT RIGHTS: the invention disclosure(s), or the patent applications and patents as listed in
Appendix A of this Agreement, or the VALID CLAIMs of such patent applications and patents, or the inventions described and claimed
therein, or any divisions, extensions, re-examinations or continuations of the patent applications and patents as listed in Appendix
A, or specific claims of any continuations-in-part of such patent applications and patents to the extent the specific claims are
directed to subject matter described in the patent applications and patents listed in Appendix A in a manner sufficient to support
such specific claims under 35 U.S.C., or patents issuing thereon or reissues thereof, or any and all foreign patents and patent
applications corresponding thereto, or the combination of the above, all to the extent owned or controlled by TJU.

 

		1.14	RESEARCH AND DEVELOPMENT INCOME: [***].

 

		1.15	SUBLICENSEE: as used in this Agreement shall mean any third party to whom LICENSEE has granted
a license to make, have made, use and/or sell the LICENSED PRODUCT or LICENSED PROCESS under PATENT RIGHTS, or KNOW-HOW, or MATERIALS,
or the combination of the above, provided said third party has agreed in writing with LICENSEE to accept the conditions and restrictions
agreed to by LICENSEE in this Agreement.

 

		1.16	TERRITORY: all territories.

 

		1.17	TJU: Thomas Jefferson University, a nonprofit Pennsylvania educational corporation having offices
at 1020 Locust Street, M34, Philadelphia, PA 19107.

 

		1.18	VALID CLAIM: either (a) a claim of an issued patent that has not been held unenforceable or invalid
by an agency or a court of competent jurisdiction in any unappealable or unappealed decision or (b) a claim of a pending patent
application that has not been abandoned or finally rejected without the possibility of appeal or refiling and that has been pending
for less than [***] from its priority date.

 

     Page 2 of 14

     

    

 

		1.19	The terms “Public Law 96-517” and “Public Law 98-620” include all amendments
to those statutes.

 

		1.20	The terms “sold” and “sell” include, without limitation, leases and other
legal transfers and similar transactions involving CONSIDERATION.

 

Article
II

REPRESENTATIONS

 

		2.1	For the technologies DES_SCO.004 and DES_SCO.005, TJU is owner by assignment from inventors of
their entire right, title and interest in the PATENT RIGHTS, or KNOW-HOW, or MATERIALS, or the combination of the above, and in
the inventions described and claimed therein as listed in Appendix A. For the technology DES_SCO.011, TJU and the University of
Tennessee are joint owners. For TJU’s portion of the technology DES_SCO.011, TJU by assignment from inventors at TJU of their
entire right, title and interest in the PATENT RIGHTS, or KNOW-HOW, or MATERIALS, or the combination of the above, and in the inventions
described and claimed therein as listed in Appendix A.

 

		2.2	TJU has the authority to issue licenses under PATENT RIGHTS, or KNOW-HOW, or MATERIALS, or the
combination of the above.

 

		2.3	TJU is committed to the policy that ideas or creative works produced at TJU should be used for
the greatest possible public benefit, and believes that every reasonable incentive should be provided for the prompt introduction
of such ideas into public use, all in a manner consistent with the public interest.

 

		2.4	LICENSEE is prepared and intends to diligently develop the LICENSED PRODUCTS and to bring LICENSED
PRODUCTS to market which are subject to this Agreement.

 

		2.5	LICENSEE is desirous of obtaining an exclusive license in the TERRITORY within the FIELD in order
to practice the above-referenced inventions covered by PATENT RIGHTS, or KNOW-HOW, or MATERIALS, or the combination of the above,
in the United States and in certain foreign countries, and to manufacture, use and sell in the commercial market the products made
in accordance therewith, and TJU is desirous of granting such a license to LICENSEE in accordance with the terms of this Agreement.

 

Article
III

GRANT OF RIGHTS

 

		3.1	TJU hereby grants to LICENSEE and LICENSEE accepts, subject to the terms and conditions hereof,
in the TERRITORY and within the FIELD an exclusive commercial license under PATENT RIGHTS, and KNOW-HOW, and MATERIALS, individually
or the combination of the above, to make and have made, to use and have used, to sell and have sold, to offer for sale, to import,
to export, to research, develop and improve the LICENSED PRODUCTS, and to practice the LICENSED PROCESSES, for the life of the
PATENT RIGHTS. In order to provide LICENSEE with commercial exclusivity for as long as the license under the PATENT RIGHTS, or
KNOW-HOW, or MATERIALS, or the combination of the above, remains exclusive, TJU agrees so long as LICENSEE is not in default of
this Agreement that it will not grant licenses under PATENT RIGHTS, or KNOW-HOW, or MATERIALS, or the combination of the above,
in the TERRITORY and within the FIELD to others except as required by TJU’s obligations in Section 3.3(a) or as permitted
in Section 3.3(b).

 

		3.2	TJU also grants to LICENSEE the right to issue sublicenses in the TERRITORY and within the FIELD
to third parties to make, have made, use, sell, offer for sale, import, export, research, develop and improve LICENSED PRODUCTS
and to practice LICENSED PROCESSES, providing LICENSEE has current exclusive rights thereto from TJU under this Agreement. To the
extent applicable, such sublicenses shall include all of the rights of and obligations due to TJU (and, if applicable, the United
States Government) that are contained in this Agreement. LICENSEE shall collect and guarantee payment of all royalties due TJU
from SUBLICENSEES, and summarize and deliver all reports due TJU from SUBLICENSEES.

 

     Page 3 of 14

     

    

 

		3.3	The granting and exercise of this license is subject to the following conditions:

 

		(a)	TJU’s “Patent Policy”, Public Law 96-517, Public Law 98-620, and TJU’s
pre-existing obligations under agreements with other sponsors of research. Any right granted in this Agreement greater than that
permitted under Public Law 96-517, or Public Law 98-620, shall be subject to modification as may be required to conform to the
provisions of those statutes.

 

		(b)	TJU reserves the right to make and use, and grant to others non-exclusive licenses to make and
use for ACADEMIC RESEARCH PURPOSES the subject matter described and claimed in PATENT RIGHTS, or KNOW-HOW, or MATERIALS, or the
combination of the above.

 

		(c)	LICENSEE shall use commercially reasonable diligent efforts to effect introduction of the LICENSED
PRODUCTS and/or LICENSED PROCESSES into the commercial market, either directly or through one or more SUBLICENSEEs, as soon as
practicable, consistent with sound and reasonable business practice and judgment; thereafter, until the expiration of this Agreement,
LICENSEE shall endeavor to keep LICENSED PRODUCTS and/or LICENSED PROCESSES reasonably available to the public.

 

		(d)	At any time after five (5) years from the effective date of this Agreement, TJU may terminate or
render this license non-exclusive if, in TJU’s reasonable good faith judgment, the progress reports furnished by LICENSEE
substantially demonstrate that LICENSEE:

 

		(i)	has not put the licensed subject matter into commercial use in the country or countries hereby
licensed, directly or through a sublicense, and/or is not keeping the licensed subject matter reasonably available to the public;
or

 

		(ii)	is not engaged in research, development, manufacturing, marketing or sublicensing activity reasonably
appropriate to achieving 3.3(d)(i).

 

		(e)	In all sublicenses granted by LICENSEE hereunder other than research sublicenses, LICENSEE shall
include a requirement that the SUBLICENSEE(s) use its commercially reasonable efforts to bring the subject matter of the sublicense
into commercial use as quickly as is reasonably possible. LICENSEE shall further provide in such sublicenses that such sublicenses
are subject and subordinate to the terms and conditions of this Agreement, except: (i) the SUBLICENSEE may not further sublicense;
and (ii) the rate of royalty on NET SALES paid by the SUBLICENSEE to the LICENSEE. Copies of all executed sublicense agreements
shall be provided within [***] of execution to TJU. TJU agrees to maintain any information contained in such provisions in confidence,
except as otherwise required by law, however, TJU may include in its usual reports annual amounts of royalties paid.

 

		(f)	TJU understands and acknowledges that LICENSEE will be spending considerable resources, both human
and financial on the development of the LICENSED PRODUCTS and/or LICENSED PROCESSES in an effort to obtain the necessary approvals
of LICENSED PRODUCTS and/or LICENSED PROCESSES within the FIELD and in the TERRITORY. LICENSEE further acknowledges that TJU has
advised LICENSEE that it is TJU’s mission to make the LICENSED PRODUCTS and/or LICENSED PROCESSES available to the public.

 

		(g)	To the extent that federal funds are used to support research leading to the PATENT RIGHTS, or
KNOW-HOW, or MATERIALS, or the combination of the above, LICENSEE shall cause any LICENSED PRODUCT produced for sale or LICENSED
PROCESSES used by LICENSEE or SUBLICENSEES in the United States to be manufactured or utilized substantially in the United States
during the period of exclusivity of this license in the United States.

 

		3.4	All rights reserved to the United States Government and others under Public Law 96-517, and Public
Law 98-620, shall remain and shall in no way be affected by this Agreement.

 

     Page 4 of 14

     

    

 

Article
IV

ROYALTIES

 

		4.1	LICENSEE shall pay to TJU a one-time, non-creditable, non-refundable license fee in the sum of
thirty thousand dollars ($30,000) ($10,000 for DES_SCO.004, $10,000 for DES_SCO.005, and $10,000 for DES_SCO.011) within [***]
upon execution of this Agreement.

 

		4.2	As consideration for the rights granted hereunder, LICENSEE shall pay to TJU during the term of
this Agreement a royalty in the form of stock of LICENSEE. LICENSEE shall issue to TJU shares of common stock (“Shares”)
equivalent to [***] of the number of outstanding shares of LICENSEE on the effective date of this Agreement, pursuant to the terms
of a mutually acceptable Stock Subscription Agreement, provided, however, that TJU shall be, now and in the future, subject to
and enter into such agreements and related documents as are required of other stockholders of LICENSEE. [***]

 

TJU’s ownership rights
to Shares shall not be affected should the license pursuant to this Agreement be converted to a non-exclusive one.

 

	4.3	(a)	LICENSEE shall pay to TJU during the term of this Agreement a royalty of [***] of NET SALES by LICENSEE and SUBLICENSEES in any
countries where there is a VALID CLAIM; and

 

		(b)	LICENSEE shall pay to TJU during the term of this Agreement a royalty of [***] of NET SALES by
LICENSEE and SUBLICENSEES in any countries where there is no VALID CLAIM.

 

		4.4	In the case of sublicenses, LICENSEE shall pay to TJU a royalty of [***] of all NON-ROYALTY SUBLICENSE
INCOME.

 

		4.5	[***]

 

		4.6	As consideration for the exclusive rights granted hereunder, LICENSEE shall pay to TJU during the
term of this Agreement the following one-time cash milestone payments within [***] of the occurrence of such milestone event (time
of payment is of the essence) as follows:

 

		(i)	[***]; and

 

		(ii)	[***].

 

		4.7	Within [***] after execution of this Agreement, LICENSEE shall pay to TJU a non-creditable, non-refundable
material fee in the amount of twelve thousand dollars ($12,000) for the materials: (1) [***] and (2) [***] ($6,000 for each material).
Other than the two materials mentioned here: [***], LICENSEE’s use of any additional materials, that are covered under the
PATENT RIGHTS, or KNOW-HOW, or MATERIALS, or the combination of the above for commercial use, shall be subject to additional agreements
between LICENSEE and TJU.

 

		4.8	Anything herein to the contrary, if the license pursuant to this Agreement is converted to a non-exclusive
one and if other non-exclusive licenses in the same field and territory are granted, the above royalties shall not exceed the royalty
rate to be paid by other licensees in the same field and territory during the term of the non-exclusive license.

 

		4.9	[***]

 

		4.10	No later than June 30 of each calendar year beginning in [***], LICENSEE shall pay to TJU a non-refundable
license maintenance royalty and/or advance on royalties. Such payments may only be credited against running royalties due and owing
for that calendar year and royalty reports shall reflect such a credit. Such credits shall not be credited against milestone payments
(as listed in Section 4.5) and NON-ROYALTY SUBLICENSEE INCOME (as listed
in Section 4.3) nor against royalties due for any subsequent or preceding calendar year nor for any other payments made pursuant
to this license.

 

     Page 5 of 14

     

    

 

	 	DES_SCO.004	DES_SCO.005	DES_SCO.011
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]

 

Article
V

REPORTING

 

		5.1	Six (6) months after signing this Agreement, LICENSEE shall provide to TJU a written research and
development plan under which LICENSEE intends to bring the subject matter of the licenses granted hereunder into commercial use
upon execution of this Agreement. Such plan includes projections of sales and proposed marketing efforts.

 

		5.2	No later than [***] after June 30 of each calendar year, LICENSEE shall provide to TJU a detailed
written annual progress report describing progress on research and development, regulatory approvals, manufacturing, sublicensing,
marketing and sales during the most recent twelve (12) month period ending June 30 and plans for the forthcoming year. If multiple
technologies are covered by the license granted hereunder, the progress report shall provide the information set forth above for
each technology. If progress differs from that anticipated in the plan required under Section 5.1, LICENSEE shall explain the reasons
for the difference and propose a modified research and development plan for TJU’s review. LICENSEE shall also provide any
reasonable additional data TJU reasonably requires to evaluate LICENSEE’s performance.

 

		5.3	LICENSEE shall report to TJU the date of first sale of LICENSED PRODUCTS (or results of LICENSED
PROCESSES) in each country within [***] of occurrence.

 

	5.4	(a)	LICENSEE shall submit to TJU within [***] after June 30 of each calendar year, a Royalty Report setting forth for such year at
least the following information:

 

		(i)	the number of LICENSED PRODUCTS sold by LICENSEE, its AFFILIATES and SUBLICENSEEs in each country;

 

		(ii)	identity of the technolog(ies), DES_SCO.004, DES_SCO.005, and/or DES_SCO.011, utilized in each
LICENSED PRODUCT sold by LICENSEE, its AFFILIATES and SUBLICENSEEs in each country;

 

		(iii)	total billings and amounts actually received for such LICENSED PRODUCTS;

 

		(iv)	an accounting for all LICENSED PROCESSES used or sold;

 

		(v)	deductions applicable to determine the NET SALES thereof;

 

		(vi)	the amount of NON-ROYALTY SUBLICENSE INCOME received by LICENSEE; and

 

		(vii)	the amount of royalty due thereon, or, if no royalties are due to TJU for any reporting period,
the statement that no royalties are due.

 

Such report shall be certified
as correct by an officer of LICENSEE and shall include a detailed listing of all deductions from royalties.

 

		(b)	LICENSEE shall pay to TJU with each such Royalty Report the amount of royalty due with respect
to such year.

 

     Page 6 of 14

     

    

 

		(c)	All payments due hereunder shall be deemed received when funds are credited to TJU’s bank
account and shall be payable by check or wire transfer in United States dollars. Conversion of foreign currency to U.S. dollars
shall be made at [***]. No transfer, exchange, collection or other charges shall be deducted from such payments.

 

		(d)	All such reports shall be maintained in confidence by TJU except as required by law; however, TJU
may include in its usual reports annual amounts of royalties paid.

 

		(e)	Late payments shall be subject to a charge of [***], whichever is greater.

 

		5.5	In the event of acquisition, merger, change of corporate name, or reorganization, LICENSEE shall
notify TJU in writing within [***] of such event and provide TJU with reasonable assurance that such changes shall not effect payment
to TJU or the commercialization of the LICENSED PRODUCT and/or LICENSED PROCESS, and any other factors that may be relevant to
TJU’s evaluation of its consent to certain assignments pursuant to Section 10.5.

 

		5.6	If LICENSEE or any AFFILIATE or SUBLICENSEE does not qualify as a “small entity” as
provided by the United States Patent and Trademark Office, LICENSEE must notify TJU in writing immediately.

 

Article
VI

RECORD KEEPING

 

		6.1	LICENSEE shall keep, and shall require its AFFILIATES and SUBLICENSEEs to keep, accurate records
(together with supporting documentation) of LICENSED PRODUCTS and/or LICENSED PROCESSES made, used or sold under this Agreement,
appropriate to determine the amount of royalties due to TJU hereunder. Such records shall be retained for at least [***] following
the end of the reporting period to which they relate. They shall be available during normal business hours and upon prearrangement
for examination by an accountant selected by TJU, for the sole purpose of verifying reports and payments hereunder. In conducting
examinations pursuant to this Section, TJU’s accountant shall have access to all records which TJU reasonably believes to
be relevant to the calculation of royalties under Article IV.

 

		6.2	TJU’s accountant shall not disclose to TJU any information other than information relating
to the accuracy of reports and payments made hereunder unless required by law, regulation or pursuant to court order.

 

		6.3	Such examination by TJU’s accountant shall be at TJU’s expense, except that if such
examination shows an underreporting or underpayment in excess of [***] for [***] period or in excess of [***], then LICENSEE shall
pay the cost of such examination as well as any additional sum that would have been payable to TJU had the LICENSEE reported correctly,
plus interest on said sum at the rate of [***].

 

Article
VII

DOMESTIC AND FOREIGN PATENT FILING AND MAINTENANCE

 

		7.1	After execution date of this Agreement, LICENSEE shall reimburse TJU for one hundred percent (100%)
of all reasonable unreimbursed legal expenses TJU has incurred for the preparation, filing, prosecution and maintenance of PATENT
RIGHTS prior to the effective date of this Agreement. The amount of such legal expenses is approximately $17,654.90 as of March
31, 2012.

 

After execution date of this
Agreement, LICENSEE shall reimburse TJU for one hundred percent (100%) of all future reasonable unreimbursed legal expenses upon
receipt of invoices from TJU. To the extent such invoices are not paid within [***] from LICENSEE’s first receipt of such
invoice, all late payments shall be subject to interest charges of [***].

 

		7.2	TJU shall be responsible for the preparation, filing, prosecution and maintenance of any and all
patent applications and patents included in PATENT RIGHTS. TJU will instruct patent counsel to directly notify TJU and LICENSEE
and provide them copies of any official communications from the United States and foreign patent offices relating
to the prosecution and maintenance of the PATENT RIGHTS, and to provide LICENSEE and TJU with advance copies of all relevant communications
to the various patent offices, so that LICENSEE may be informed and apprised of the continuing prosecution of patent applications
in PATENT RIGHTS. LICENSEE shall have reasonable opportunities to participate in decision making on all key decisions affecting
filing, prosecution and maintenance of patents and patent applications in PATENT RIGHTS. TJU will use commercially reasonable efforts
to incorporate LICENSEE’s reasonable suggestions regarding said prosecution. TJU shall use commercially reasonable efforts
to amend any patent application to include claims reasonably requested by LICENSEE to protect LICENSED PRODUCTS and/or LICENSED
PROCESSES.

 

     Page 7 of 14

     

    

 

		7.3	TJU and LICENSEE shall cooperate fully in the preparation, filing, prosecution and maintenance
of PATENT RIGHTS and of all patents and patent applications licensed to LICENSEE hereunder, executing all papers and instruments
or requiring members of TJU to execute such papers and instruments so as to enable TJU to apply for, to prosecute and to maintain
patent applications and patents in TJU’s name in any country. TJU and LICENSEE shall provide to the other prompt notice as
to all matters which come to its attention and which may affect the preparation, filing, prosecution or maintenance of any such
patent applications or patents. In particular, LICENSEE shall immediately notify TJU in writing if LICENSEE or any AFFILIATE or
SUBLICENSEE does not qualify as a “small entity” as provided by the United States Patent and Trademark Office.

 

		7.4	LICENSEE may elect to surrender its PATENT RIGHTS in any country upon [***] written notice to TJU.
Such notice shall not relieve LICENSEE from responsibility to reimburse TJU for patent-related expenses incurred prior to the expiration
of the [***] notice period. TJU shall not have any further obligations to LICENSEE in such country after the expiration of such
[***] notice period.

 

Article
VIII

INFRINGEMENT

 

		8.1	With respect to any PATENT RIGHTS within the FIELD that are licensed to LICENSEE by TJU on an exclusive
basis pursuant to this Agreement, LICENSEE shall have the right to prosecute in its own name and at its own expense any infringement
of such patent, so long as such license is exclusive at the time of the commencement of such action. TJU agrees to notify LICENSEE
promptly of each infringement of such patents of which TJU has knowledge or becomes aware. Before LICENSEE commences an action
with respect to any infringement of such patents, LICENSEE shall give careful consideration to the views of TJU and to potential
effects on the public interest in making its decision whether or not to sue.

 

	8.2	(a)	If LICENSEE elects to commence an action as described above, TJU may, to the extent permitted
by law, elect to join as a party in that action. Regardless of whether TJU elects to join as a party, TJU shall cooperate fully
with LICENSEE in connection with any such action. Before LICENSEE names TJU as a party, LICENSEE shall consult with TJU and give
careful consideration to the views of TJU and to potential effects on the public interest in making its decision whether or not
to name TJU as a party.
	 	 	 
		(b)	If TJU elects to join as a party pursuant to Subsection (a), LICENSEE will give careful consideration
to TJU’s input regarding the infringement action.

 

		(c)	LICENSEE shall reimburse TJU for any reasonable costs TJU incurs, including reasonable attorneys’
fees, as part of an action brought by LICENSEE irrespective of whether TJU becomes a co-plaintiff.

 

		8.3	If LICENSEE elects to commence an action as described above, LICENSEE may deduct from its yearly
royalty payments to TJU with respect to the patent(s) subject to suit an amount not exceeding fifty percent (50%) of LICENSEE’s
expenses and costs of such action incurred by LICENSEE in the same calendar year, including reasonable attorneys’ fees, provided,
however, that such reduction shall not exceed fifty percent (50%) of the total royalty payments due to TJU in that calendar year.
For clarification, the total royalty payments due to TJU are the royalty payments due to TJU with respect to the patent(s) subject
at suit for each calendar year as referenced
in Section 4.3 and do not include the NON-ROYALTY SUBLICENSE INCOME referenced in Section 4.4 and the milestone payments referenced
in Section 4.6. If such LICENSEE’s expenses and costs in any one calendar year exceeds fifty percent (50%) of the amount
of royalties owed by LICENSEE for that calendar year (an “Overage”), LICENSEE may not carry such Overage to the succeeding
calendar year and reduce the royalties due to TJU from LICENSEE in such succeeding calendar years.

 

     Page 8 of 14

     

    

 

		8.4	No settlement, consent judgment or other voluntary final disposition of the suit that materially
adversely affects TJU’s rights may be entered into without the prior written consent of TJU, which consent shall not be unreasonably
withheld. An admission of liability on the part of TJU shall be reasonable grounds to withhold consent.

 

		8.5	Recoveries or reimbursements from actions commenced pursuant to this Article shall first be applied
to reimburse LICENSEE and TJU for litigation costs not paid from royalties and then to reimburse TJU for royalties deducted by
LICENSEE pursuant to Section 8.3. Any additional recoveries shall be shared by LICENSEE and TJU, [***] to LICENSEE and [***] to
TJU.

 

		8.6	If LICENSEE elects not to exercise its right to prosecute an infringement of the PATENT RIGHTS
pursuant to this Article, TJU may do so at its own expense, controlling such action and retaining all recoveries there from. LICENSEE
shall cooperate fully with TJU in connection with any such action.

 

		8.7	Without limiting the generality of Section 8.6, TJU may, at its election and by notice to LICENSEE,
establish a time limit of [***] for LICENSEE to decide whether to prosecute any infringement of which TJU has knowledge or becomes
aware. If, by the end of such [***] period, LICENSEE has not commenced such an action, TJU may prosecute such an infringement at
its own expense, controlling such action and retaining all recoveries therefrom. With respect to any such infringement action prosecuted
by TJU in good faith, LICENSEE shall pay over to TJU any payments (whether or not designated as “royalties”) made by
the alleged infringer to LICENSEE under any existing or future sublicense authorizing LICENSED PRODUCTS and/or LICENSED PROCESSES,
up to the amount of TJU’s unreimbursed litigation expenses (including, but not limited to, reasonable attorneys’ fees).

 

		8.8	If a declaratory judgment action is brought naming LICENSEE as a defendant and alleging invalidity
of any of the PATENT RIGHTS, TJU may elect to take over the sole defense of the action at its own expense. LICENSEE shall cooperate
fully with TJU in connection with any such action.

 

Article
IX

TERMINATION OF AGREEMENT

 

		9.1	This Agreement, unless terminated as provided herein, shall remain in effect until the last patent
or patent application containing a VALID CLAIM in PATENT RIGHTS has expired or been abandoned.

 

		9.2	TJU may terminate this Agreement as follows:

 

		(a)	If LICENSEE does not make a payment due hereunder and fails to cure such non-payment (including
the payment of interest in accordance with Section 5.4(e)) within [***] after the date of notice in writing of such non-payment
by TJU.

 

		(b)	If LICENSEE defaults in its obligations under Sections 10.3(c) to procure and maintain insurance
and fails to cure such default in accordance with Section 10.3(d).

 

		(c)	If, at any time after five (5) years from the effective date of this Agreement, TJU determines
in good faith that the Agreement should be terminated pursuant to Section 3.3(d).

 

		(d)	If LICENSEE shall become insolvent, shall make an assignment for the benefit of creditors, shall
have been declared bankrupt by a court of competent jurisdiction, makes use of any law or regulation for relief from creditors, or reorganizations
or restructures in order to avoid creditors. Such termination shall be effective immediately upon TJU giving written notice to
LICENSEE.

 

     Page 9 of 14

     

    

 

		(e)	If an examination by TJU’s accountant pursuant to Article VI shows an underreporting or underpayment
by LICENSEE in excess of [***].

 

		(f)	If LICENSEE is convicted of, or pleads nolo-contendere to, a felony relating to the manufacture,
use, or sale of LICENSED PRODUCTS and/or LICENSED PROCESSES.

 

		(g)	Except as provided in Subsections (a), (b), (c), (d), (e) and (f) above, if LICENSEE defaults in
a material respect in the performance of any obligations under this Agreement and the default has not been remedied within [***]
after the date of notice in writing of such default by TJU.

 

		9.3	LICENSEE shall provide, in each sublicense granted by it under this Agreement, that such sublicense
shall survive the termination of this Agreement and that LICENSEE’s interest in such sublicense shall, at TJU’s option,
either be terminated or assigned to TJU.

 

		9.4	LICENSEE may terminate this Agreement by giving [***] advance written notice of termination to
TJU. Upon termination, LICENSEE shall submit a final royalty report to TJU and any royalty payments and unreimbursed legal expenses
due to TJU shall become immediately payable. Upon termination by LICENSEE, all obligations and duties under this LICENSEE shall
cease and terminate and LICENSEE agrees to execute all reasonable documentations requested evidencing such termination.

 

		9.5	Sections 6.1, 6.2, 6.3, 7.1, 8.5, 9.3, 9.4, 9.5, 10.2, 10.3, 10.4, 10.5, 10.8 and 10.9 of this
Agreement and all other provisions of this Agreement which are intended to have effect after termination of this Agreement shall
survive termination of this Agreement for the respective durations stated therein, and where no duration is stated, shall survive
indefinitely.

 

Article
X

GENERAL

 

		10.1	TJU does not warrant the validity of the PATENT RIGHTS, KNOW-HOW, and MATERIALS, within the FIELD
licensed hereunder and makes no representations whatsoever with regard to the scope of the licensed PATENT RIGHTS, KNOW-HOW, and
MATERIALS, within the FIELD or that such PATENT RIGHTS, KNOW-HOW, and MATERIALS, may be exploited by LICENSEE, an AFFILIATE, or
SUBLICENSEE without infringing other patents.

 

		10.2	TJU EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED OR EXPRESS WARRANTIES AND MAKES NO EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE PATENT RIGHTS, KNOW-HOW, AND MATERIALS, WITHIN THE FIELD
OR INFORMATION SUPPLIED BY TJU, LICENSED PROCESSES OR LICENSED PRODUCTS CONTEMPLATED BY THIS AGREEMENT. IN NO EVENT WILL TJU BE
LIABLE FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THIS LICENSE OR THE USE OF THE INVENTIONS,
LICENSED PRODUCTS AND/OR LICENSED PROCESSES. EVEN IF ADVISED OF THE POSSIBILITY THEREOF, AND IN NO EVENT SHALL TJU’S LIABILITY
EXCEED [***].

 

	10.3	(a)	LICENSEE shall indemnify, defend and hold harmless TJU and its current or former directors,
governing board members, trustees, officers, faculty, medical and professional staff, employees, students, and agents and their
respective successors, heirs and assigns (collectively, the “Indemnitees”), from and against any claim, liability,
cost, expense, damage, deficiency, loss or obligation of any kind or nature (including, without limitation, reasonable attorney’s
fees and other costs and expenses of litigation) (collectively, “Claims”), based upon, arising out of, or otherwise
relating to any cause of action relating to product liability concerning any product, process, or service made, used or sold pursuant
to any right or license granted under this Agreement.

 

     Page 10 of 14

     

    

 

		(b)	LICENSEE shall, at its own expense, provide attorneys reasonably acceptable to TJU to defend against
any actions brought or filed against any Indemnitee hereunder with respect to the subject of indemnity contained herein, whether
or not such actions are rightfully brought.

 

		(c)	Beginning at the time any such product, process or service is being commercially distributed or
sold (other than for the purpose of obtaining regulatory approvals) by LICENSEE or by a SUBLICENSEE, an AFFILIATE or an agent of
LICENSEE, LICENSEE shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts
not less than [***] per incident and [***] annual aggregate and naming the Indemnitees as additional insureds. During clinical
trials of any such product, process or service, LICENSEE shall, at its sole cost and expense, procure and maintain commercial general
liability insurance in such equal or lesser amount as TJU shall require, naming the TJU as additional insureds. Such commercial
general liability insurance shall provide: (i) product liability coverage; and (ii) broad form contractual liability coverage for
LICENSEE’s indemnification under this Agreement. If LICENSEE elects to self-insure all or part of the limits described above
(including deductibles or retentions which are in excess of [***] annual aggregate) LICENSEE must notify TJU at least [***] in
advance of commencing any such self-insurance program and such self-insurance program must be acceptable to TJU. The minimum amounts
of insurance coverage required shall not be construed to create a limit of LICENSEE’s liability with respect to its indemnification
or other material obligations under this Agreement.

 

		(d)	LICENSEE shall provide TJU with written evidence of such insurance upon request of TJU. LICENSEE
shall provide TJU with written notice at least [***] prior to the cancellation, non-renewal or material change in such insurance;
if LICENSEE does not obtain replacement insurance providing comparable coverage within such [***] period, TJU shall have the right
to terminate this Agreement effective at the end of such [***] period without notice or any additional waiting periods.

 

		(e)	LICENSEE shall maintain such commercial general liability insurance beyond the expiration or termination
of this Agreement during: (i) the period that any product, process, or service, relating to, or developed pursuant to, this Agreement
is being commercially distributed or sold by LICENSEE or by a SUBLICENSEE, an AFFILIATE or agent of LICENSEE; and (ii) a reasonable
period after the period referred to in Subsection (e)(i) above which in no event shall be less than [***].

 

		10.4	LICENSEE shall not use TJU’s name or insignia, or any adaptation of them, or the name of
any of TJU’s inventors in any advertising, publicity, promotional activities or sales literature without the prior written
approval of TJU except in announcing to the public the existence of this Agreement. Nothing contained in this Agreement shall be
construed as conferring any right to use in advertising, publicity, or other promotional activities any name, trade name, trademark,
or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing). Unless
required by law, the use by LICENSEE of the name, “Thomas Jefferson University” or the name of any campus of Thomas
Jefferson University is expressly prohibited. Notwithstanding anything to the contrary stated above, LICENSEE may disclose that
the PATENT RIGHTS have been licensed from TJU in business plans, company presentations and other factual statements relating to
LICENSEE, its technology or its products.

 

		10.5	This Agreement and the rights and duties hereunder may not be assigned by either party without
first obtaining the written consent of the other which consent will not be unreasonably withheld. Any such purported assignment,
without the written consent of the other party, will be null and of no effect. Notwithstanding the foregoing, LICENSEE may assign
this Agreement to a purchaser, merging, or successor in-interest or acquirer of substantially all of the LICENSEE’s assets
or business and/or pursuant to any reorganization qualifying under section 368 of the Internal Revenue Code of 1986 as amended,
as may be in effect at such time.

 

		10.6	The interpretation and application of the provisions of this Agreement shall be governed by the
laws of the Commonwealth of Pennsylvania.

 

     Page 11 of 14

     

    

 

		10.7	LICENSEE shall comply with all applicable laws and regulations. In particular, it is understood
and acknowledged that the transfer of certain commodities and technical data is subject to United States laws and regulations controlling
the export of such commodities and technical data, including all Export Administration Regulations of the United States Department
of Commerce. These laws and regulations among other things, prohibit or require a license for the export of certain types of technical
data to certain specified countries. LICENSEE hereby agrees and gives written assurance that it will comply with all United States
laws and regulations controlling the export of commodities and technical data, that it will be solely responsible for any violation
of such by LICENSEE or its AFFILIATES or SUBLICENSEES, and that it will defend and hold TJU harmless in the event of any legal
action of any nature occasioned by such violation.

 

		10.8	LICENSEE agrees: (i) to obtain all regulatory approvals required for the manufacture and sale of
LICENSED PRODUCTS and/or LICENSED PROCESSES; and (ii) to utilize appropriate patent marking on such LICENSED PRODUCTS and/or LICENSED
PROCESSES. LICENSEE also agrees to register or record this Agreement (as appropriately redacted) as is required by law or regulation
in any country where the license is in effect.

 

		10.9	Any notices to be given hereunder shall be sufficient if signed by the party (or party’s
attorney) giving same and either: (i) delivered in person; (ii) mailed certified mail return receipt requested; or (iii) faxed
to other party if the sender has evidence of successful transmission and if the sender promptly sends the original by ordinary
mail, in any event to the following addresses:

 

If to LICENSEE:

Immunome, Inc.

100 East Lancaster Avenue

LIMR Building, Room #222

Wynnewood, PA 19096

Attention: [***]

Phone: [***]

Fax: [***]

 

If to TJU:

Office of Technology Transfer & Business Development

Thomas Jefferson University

1020 Locust Street, Suite M34

Philadelphia, PA 19107

Attention: Executive Director, Office of Technology
Transfer & Business Development

Phone: [***]

Fax: [***]

 

With a copy to TJU University Counsel at

University Counsel

Thomas Jefferson University

1020 Walnut Street, 6th Floor

Philadelphia, PA 19107

Phone: [***]

Fax: [***]

 

By such notice either party may
change their address for future notices. Notices delivered in person shall be deemed given on the date delivered. Notices sent
by fax shall be deemed given on the date faxed. Notices mailed shall be deemed given five (5) days following the date postmarked
on the envelope.

 

		10.10	Should a court of competent jurisdiction later hold any provision of this Agreement to be invalid,
illegal, or unenforceable, and such holding is not reversed on appeal, it shall be considered severed from this Agreement. All
other provisions, rights and obligations shall continue without regard to the severed provision, provided that the remaining provisions
of this Agreement are in accordance with the intention of the parties.

 

     Page 12 of 14

     

    

 

 

		10.11	In the event of any controversy or claim arising out of or relating to any provision of this Agreement
or the breach thereof, the parties shall try to settle such conflict amicably between themselves. Subject to the limitation stated
in the final sentence of this section, any such conflict which the parties are unable to resolve promptly shall be settled through
arbitration conducted in accordance with the rules of the [***]. The demand for arbitration shall be filed within a reasonable
time after the controversy or claim has arisen, and in no event after the date upon which institution of legal proceedings based
on such controversy or claim would be barred by the applicable statute of limitation. Such arbitration shall be held in [***].
The award through arbitration shall be final and binding. Either party may enter any such award in a court having jurisdiction
or may make application to such court for judicial acceptance of the award and an order of enforcement, as the case may be. Notwithstanding
the foregoing, either party may, without recourse to arbitration, assert against the other party a third-party claim or cross-claim
in any action brought by a third party, to which the subject matter of this Agreement may be relevant. The prevailing party in
any arbitration shall be afforded reasonable costs and attorney fees. Notwithstanding any other provision of this Agreement to
the extent any other provision is inconsistent herewith, no arbitrator(s) or any other third party involved in resolving or otherwise
addressing any dispute may limit, expand or otherwise modify the terms of this Agreement. The provisions of this Section shall
not apply to:

 

		(i)	prevent a party from seeking a temporary restraining order or injunctive or other equitable relief
with respect to a breach (or attempted breach) of this Agreement by the other party;

 

		(ii)	prevent a party from instituting litigation or other formal proceedings to the extent necessary
(i) to avoid the expiration of any applicable limitations period or (ii) to preserve a superior position with respect to other
creditors; or

 

		(iii)	to any claim with respect to ownership or infringement of PATENT RIGHTS.

 

Such claims (described in subsections
(i) through (iii) above) will not be subject to arbitration or other alternate dispute resolution and instead will be subject to
judicial resolution, and either party may apply to any court of competent jurisdiction for such relief.

 

		10.12	This Agreement constitutes the entire understanding between the parties and neither party shall
be obligated by any amendment, modifications, condition or representation other than those expressly stated herein or as may be
subsequently agreed to by the parties hereto in writing.

 

		10.13	This Agreement may be executed in two or more counterparts, each of which shall be deemed an original
and all of which shall together be deemed to constitute one Agreement.

 

		10.14	The failure of any party at any time to enforce its rights hereunder strictly in accordance with
the same shall not be construed as having created a custom contrary to the specific provisions hereof or as having in any way modified
or waived same.

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be executed by their duly authorized representatives.

 

	Thomas Jefferson University  	 	Immunome, Inc.
	 	 	 
	/s/ Steven E. McKenzie, M.D., Ph.D.	 	/s/ Timothy J. Pelura, Ph.D.
	Steven E. McKenzie, M.D., Ph.D.	 	Timothy J. Pelura, Ph.D.
	Vice President for Research	 	President and CEO
	 	 	 
	6/11/12	 	June 6, 2012
	Date	 	Date

 

    Page 13 of 14

     

    

 

Appendix A

 

The following comprise PATENT RIGHTS:

 

[***]

 

    Page 14 of 14

     

    

 

FIRST AMENDMENT TO LICENSE
AGREEMENT TJU IMMUNOME

 

This First Amendment to License Agreement
(“AMENDMENT”), is entered into as of the 19th of October, 2017 (“EFFECTIVE DATE”), by and
among Thomas Jefferson University (“TJU”) and Immunome, Inc. (“COMPANY”) (collectively, the
 “Parties”).

 

WHEREAS the Parties have entered into an
Exclusive License Agreement with an effective date of the 1st of June, 2012 (the “LICENSE AGREEMENT”);

 

WHEREAS, the Parties desire to amend the
License Agreement to modify certain terms thereof;

 

NOW, THEREFORE, in consideration of the
terms and conditions set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, intending to be legally bound, the parties hereto agree as follows:

 

Any capitalized term not separately defined
in this Amendment shall have the meaning ascribed to it in the License Agreement.

 

		1.	The Parties hereby agree to amend and replace the first sentence of Section 3.3(e) of the License Agreement in its entirety
with the following:

 

In all sublicenses granted by LICENSEE hereunder other
than research sublicenses, LICENSEE shall use its commercially reasonable efforts to include a requirement that the SUBLICENSEE(s)
use its commercially reasonable efforts to bring the subject matter of the sublicense into commercial use as quickly as is reasonably
possible.

 

		2.	The Parties hereby agree to amend and replace Section 4.4 of the License Agreement in its entirety with the following:

 

4.4       In the
case of sublicenses, LICENSEE shall pay to TJU a royalty of [***] of all NON-ROYALTY SUBLICENSE INCOME. For the avoidance of doubt,
NON-ROYALTY SUBLICENSE INCOME does not include royalties on NETS SALES. Notwithstanding the foregoing, if, in any sublicense of
the PATENT RIGHTS for a specified LICENSED PRODUCT, COMPANY or an AFFILIATE also grants to the SUBLICENSEE rights to other patents
owned or controlled by [***].

 

		3.	The Parties hereby agree to amend and replace Section 4.6 in its entirety with the following:

 

4.6 As consideration for the exclusive rights granted
hereunder, LICENSEE shall pay to TJU during the term of this Agreement the following one-time cash milestone payments within [***]
of the occurrence of such milestone event (time of payment is of the essence) as follows:

 

(i) [***];

 

    FIRST AMENDMENT TO LICENSE AGREEMENT TJU_IMMUNOME
 Page 1 of 3

     

    

 

(ii) [***];

 

and

 

(iii) [***].

 

For the avoidance of doubt each of the above milestone payment
shall become payable only once upon the first instance to occur of a triggering event in any jurisdiction, and whether by LICENSEE,
SUBLICENSEE or any AFFILIATE.

 

		4.	The Parties agree to amend and replace Section 1.8 of the License Agreement in its entirety with the following:

 

LICENSEE: Immunome, Inc., a corporation organized under
the laws of Delaware and having a principal place of business at 665 Stockton Drive, Suite 300, Exton, PA 19341.

 

		5.	Term of Amendment. This Amendment shall be in effect from the Effective Date and shall continue
for the term of the License Agreement.

 

		6.	Full Force and Effect. Except as specifically modified or amended by the terms of this Amendment, the License Agreement
and all provisions contained therein are, and shall continue, in full force and effect and are hereby ratified and confirmed.

 

		7.	Integration. This Agreement contains the entire agreement of the parties with regard to amending the License Agreement,
and supersedes and replaces any prior agreements as to that matter. This Agreement may not be changed or modified, in whole or
in part, except by an instrument in writing signed by TJU and Immunome.

 

		8.	Counterparts. This Amendment may be executed in any number of separate counterparts, each of which shall be deemed to
be an original and all of which together shall be deemed to be one and the same instrument.

 

		9.	Miscellaneous. This Amendment shall be binding upon all the parties to the License Agreement and their respective successors
and assigns.

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment
to be duly executed and delivered by their proper and duly authorized officers as of the day and year first above written.

 

[Signature page follows]

 

    FIRST AMENDMENT TO LICENSE AGREEMENT TJU_IMMUNOME
 Page 2 of 3

     

    

 

Agreed:

 

THOMAS JEFFERSON UNIVERSITY:

 

Name: Rose Ritts, PhD

Title: Executive Vice President and Chief Innovation Officer

 

	Signature: 	/s/ Rose Ritts	 

 

IMMUNOME, INC.

 

NAME: Michael J. Morin, PhD

Title: President and CEO

 

	Signature: 	/s/ Michael J. Morin	 

 

    FIRST AMENDMENT TO LICENSE AGREEMENT TJU_IMMUNOME
 Page 3 of 3

     

    

 

SECOND AMENDMENT TO LICENSE AGREEMENT

 

This Second Amendment
to License Agreement (“AMENDMENT”), is entered into as of the 28th of July, 2020 (“EFFECTIVE
DATE”), by and among Thomas Jefferson University (“TJU”) and Immunome, Inc. (“COMPANY”)
(collectively, the “Parties”).

 

WHEREAS the Parties
have entered into an Exclusive License Agreement with an effective date of the 1st of June, 2012, as amended by the
First Amendment to the License Agreement, dated October 19, 2017. (the Exclusive License Agreement, as so amended, the “LICENSE
AGREEMENT”):

 

WHEREAS, the Parties
desire to modify certain terms of the License Agreement as set forth in this Amendment; and

 

WHEREAS, any capitalized
term not separately defined in this Amendment shall have the meaning ascribed to it in the License Agreement.

 

NOW, THEREFORE, in consideration
of the terms and conditions set forth herein and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, intending to be legally bound, the parties hereto agree as follows:

 

		1.	Amendments. Section 4.3 of the License Agreement is amended and restated in its entirety
as follows:

 

		4.3	(a)Except as provided in Section 4.3(c), LICENSEE shall pay to TJU during the term of this Agreement
a royalty of [***] of NET SALES by LICENSEE and SUBLICENSEES in any countries where there is a VALID CLAIM; and

 

(b)  
Except as provided in Section 4.3(c), LICENSEE shall pay to TJU during the term of this Agreement a royalty of [***] of
NET SALES by LICENSEE and SUBLICENSEES in any countries where there is no VALID CLAIM.

 

(c)   The
royalty for NET SALES of LICENSED PRODUCTS or LICENSED PROCESSES by a SUBLICENSEE under an agreement between LICENSEE and
such SUBLICENSEE entered into before [***] (as defined below for such LICENSED PRODUCT or LICENSED PROCESS (“OTHER NET
SALES”) shall be [***] of the royalty actually paid by the SUBLICENSEE to LICENSEE; provided that such agreement
between COMPANY and such SUBLICENSEE provides for a [***] or less percentage royalty on net sales of such LICENSED PRODUCT
and/or LICENSED PROCESS to be paid to COMPANY by SUBLICENSEE. Where such agreement provides for more than a [***] royalty,
then the provisions of Sections 4.3(a) and (b) shall apply. Where such agreement provides for a [***] or less royalty and a
royalty that exceeds [***] (e.g., a scaled royalty based on the amount of net sales), then the provisions of this Section
4.3(c) shall apply for the royalties that are [***] or below and the provisions of Sections 4.3(a) and (b) shall apply for
the royalties that exceed [***].

 

    SECOND AMENDMENT TO LICENSE AGREEMENT TJU_IMMUNOME
 Page 1 of 3

     

    

 

For purposes of
calculating the royalties under Sections 4.3(a) and (b), where royalties on OTHER NET SALES are paid under this Section 4.3(c),
then such OTHER NET SALES shall be disregarded and excluded from the definition of NET SALES.

 

Notwithstanding
the foregoing, in any sublicense of a LICENSED PRODUCT or LICENSED PROCESS, if COMPANY or an AFFILIATE also grants rights to other
licensed products or patents owned or controlled by [***],
the modified royalty due on OTHER NET SALES provided under this Section 4(c) shall only take effect if [***].

 

For the purposes
of this SECTION 4.3(c) [***] shall mean [***].

 

		2.	Term of Amendment. This Amendment shall be in effect from the Effective Date and shall continue
for the term of the License Agreement.

 

		3.	Full Force and Effect. Except as specifically modified or amended by the terms of this Amendment,
the License Agreement and all provisions contained therein are, and shall continue, in full force and effect and are hereby ratified
and confirmed.

 

		4.	Integration. The Agreement, as amended by this Amendment, contains the entire agreement
of the parties with regard to this Amendment and the Agreement, and supersedes and replaces any prior agreements as to that matter.
Neither this Amendment nor the Agreement may be changed or modified, in whole or in part, except by an instrument in writing signed
by TJU and Company.

 

		5.	Counterparts. This Amendment may be executed in any number of separate counterparts, each
of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.

 

		6.	Miscellaneous. This Amendment shall be binding upon all the parties to the License Agreement
and their respective successors and assigns.

 

IN WITNESS WHEREOF. the parties hereto have caused this Amendment
to be duly executed and delivered by their proper and duly authorized officers as of the day and year first above written.

 

    SECOND AMENDMENT TO LICENSE AGREEMENT TJU_IMMUNOME
 Page 2 of 3

     

    

 

Agreed:

 

THOMAS JEFFERSON UNIVERSITY

 

Name: Rose Ritts, PhD

Title: Executive Vice President and Chief Innovation Officer

 

	Signature: 	/s/ Rose Ritts	 

 

IMMUNOME, INC.

 

Name: Purnanand Sarma

Title: President & CEO

 

	Signature: 	/s/ Purnanand D. Sarma	 

 

    SECOND AMENDMENT TO LICENSE AGREEMENT TJU_IMMUNOME
 Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]